KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
Currículum de kol para Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi: Estadísticas de influencia
Sacar un reporte
| Concept | World rank |
|---|---|
| anorexia antineoplastic agents | #1 |
| patients dfs predictions | #1 |
| flaxseed hot flashes | #1 |
| neuropathic pain difficulty | #1 |
| pregabalin paclitaxel | #1 |
| dfs predictions adjuvant | #1 |
| neuropathy data | #1 |
| rose geranium | #1 |
| anthracycline data | #1 |
| pregenplus | #1 |
| prevention paps | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| gene arhgef10 | #1 |
| chamomile mouthwash toxicity | #1 |
| vaginal cytology women | #1 |
| daily questionnaires | #1 |
| dronabinol megestrol acetate | #1 |
| premenopause radiotherapy | #1 |
| flaxseed bar lignans | #1 |
| trust oncologists competence | #1 |
| uniscale qol baseline | #1 |
| baseline assessment week | #1 |
| placebo 15 points | #1 |
| gabapentin arm | #1 |
| cancer anorexia cachexia | #1 |
| coasting phenomenon | #1 |
| flashes common | #1 |
| ulabtka placebo cream | #1 |
| patients gabapentin | #1 |
| leap 12 months | #1 |
| prevention oral cryotherapy | #1 |
| testosterone improvements | #1 |
| toxicities opioids | #1 |
| routine feces sensitivity | #1 |
| patientreported nasal symptoms | #1 |
| isaes | #1 |
| flashes women | #1 |
| rs9657362 | #1 |
| deprivation symptoms | #1 |
| rs2294039 | #1 |
| neuropathy 20 | #1 |
| paclitaxel favor | #1 |
| ocular ice packs | #1 |
| hot flash frequency | #1 |
| ncctg n08c3 | #1 |
| cipn function | #1 |
| venous toxicity fosaprepitant | #1 |
| purposehot | #1 |
| patients hot flashes | #1 |
| populations neurologic humans | #1 |
| n00cb | #1 |
| therapy numbness | #1 |
| ulabtka arm | #1 |
| backgrounddehydroepiandrosterone | #1 |
| study dmc assay | #1 |
| oral mucositisrelated pain | #1 |
| leucovorin breast | #1 |
| bupropion nicotine dependence | #1 |
| nonhormonal therapies paroxetine | #1 |
| aminobutyric acid adt | #1 |
| amines antidepressive | #1 |
| oncologists competence 95ci | #1 |
| control hot flashes | #1 |
| individual patients understanding | #1 |
| hec cisplatin therapy | #1 |
| glutathione cipn | #1 |
| cipn20 | #1 |
| aes placebo arm | #1 |
| neuropathy prevention | #1 |
| toxicity ocular | #1 |
| leap lymphedema | #1 |
| progestational agents patients | #1 |
| oral mucositis alopecia | #1 |
| attribution percentage | #1 |
| cinv day | #1 |
| antibiotic lozenge placebo | #1 |
| bellergal | #1 |
| mascc isoo guidelines | #1 |
| breakthrough nausea patients | #1 |
| placebos pregabalin quality | #1 |
| patient followup studies | #1 |
| baseline neuropathic pain | #1 |
| antibiotic lozenge | #1 |
| placebo mouthwash | #1 |
| baseline fsfi score | #1 |
| efficacy gabapentin | #1 |
| 2007 guidelines guideline | #1 |
| patients 10 range | #1 |
| metastatic disease initiation | #1 |
| balance gait testing | #1 |
| skin dermatitis trials | #1 |
| replacement testosterone andropause | #1 |
| flashes treatment | #1 |
| n08ca association | #1 |
| numbness scores | #1 |
| male megestrol life | #1 |
| stomatitis administration | #1 |
| topic peripheral neuropathy | #1 |
| flashes patients | #1 |
| resected cutaneous melanomas | #1 |
| current trial | #1 |
| severe stomatitis | #1 |
| compassionate honesty | #1 |
| management genital symptoms | #1 |
| neuronal uptake transporters | #1 |
| diphenhydraminelidocaineantacid | #1 |
| baseline prognosis values | #1 |
| cryotherapy mucositis | #1 |
| 5 weeks device | #1 |
| cryotherapy auc | #1 |
| antiemetic prescribing | #1 |
| a151408 | #1 |
| cachexia studies | #1 |
| numeracy benefit | #1 |
| life megestrol acetate | #1 |
| n08c3 | #1 |
| creatine placebo groups | #1 |
| appetite stimulation patients | #1 |
| antacid mouthwash | #1 |
| preceding 2 months | #1 |
| 43 oral complications | #1 |
| hormone deprivation | #1 |
| painful oxaliplatininduced cipn | #1 |
| megestrol acetate nausea | #1 |
| improvements hot flashes | #1 |
| acetate anorexia | #1 |
| treatment symptom intervention | #1 |
| guidelineendorsed treatment | #1 |
| numeracy adjuvant | #1 |
| efficacy agent | #1 |
| phase iii evaluation | #1 |
| treatment cipn | #1 |
| paclitaxel study arms | #1 |
| alliance a151724 | #1 |
| preliminary evidence improvement | #1 |
| leucovorin breast cancer | #1 |
| agents cyclohexanecarboxylic | #1 |
| hot flashes acceptability | #1 |
| flashes venlafaxine | #1 |
| tools hypothetical scenarios | #1 |
| δ − 95 | #1 |
| polyneuropathy allelic variability | #1 |
| attribution clinical trials | #1 |
| residual hot flashes | #1 |
| myalgias arthralgias | #1 |
| cipn common | #1 |
| balance impairments patients | #1 |
| overview oncology providers | #1 |
| sham acupuncture participants | #1 |
| gabapentin baseline week | #1 |
| peripheral neuropathy paclitaxel | #1 |
| longitudinal continuation | #1 |
| dfs 5fu | #1 |
| shooting burning | #1 |
| small cell continuity | #1 |
| favor placebo | #1 |
| neoplasm recurrence apixaban | #1 |
| patients megestrol acetate | #1 |
| gabapentin aminobutyric acid | #1 |
| alliance n08ca | #1 |
| patients underdescribers | #1 |
| bakplo | #1 |
| hot flash mechanism | #1 |
| chemotherapy regimen type | #1 |
| cachexia cancer anorexia | #1 |
| placebo pilot trials | #1 |
| flashes objective | #1 |
| supportive nsclc | #1 |
| historical placebo response | #1 |
| qol reported difficulty | #1 |
| drug humans interferons | #1 |
| authors 30 minutes | #1 |
| symptom intervention | #1 |
| decrease hot | #1 |
| tpn death | #1 |
| oestrogen survivors | #1 |
| pilot study minocycline | #1 |
| supportive cryotherapy | #1 |
| cisplatin therapy cinv | #1 |
| women male megestrol | #1 |
| lenolidamide | #1 |
| life leap | #1 |
| leap rom | #1 |
| incurable cancer records | #1 |
| treatment alteration | #1 |
| flashes androgen | #1 |
| udi δ − | #1 |
| enoxaparin cvte | #1 |
| ulabtka | #1 |
| patients paclitaxel polyneuropathy | #1 |
| newer antidepressants gabapentin | #1 |
| infliximab lung | #1 |
| differences neuropathy syndromes | #1 |
| 5fuinduced stomatitis | #1 |
| gsm fsfi | #1 |
| alliance study a221102 | #1 |
| safety oestrogen | #1 |
| ganglion surveys | #1 |
| hfs symptoms patients | #1 |
| relatedness treatment | #1 |
| drowsiness doxepin mouthwash | #1 |
| flashes stellate | #1 |
| numbness tingling | #1 |
| nonhormonal agents treatment | #1 |
| olanzapine projects vomiting | #1 |
| induced cipn | #1 |
| adam vte trial | #1 |
| megestrol acetate weeks | #1 |
| fsfi udi | #1 |
| antineoplastic agents nrs | #1 |
| duloxetine response patients | #1 |
| pharmacological targeting oct2 | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| lymphedema hrqol outcomes | #1 |
| symptoms hands | #1 |
| daily hot | #1 |
| taxane infusion | #1 |
| oral cryotherapy patients | #1 |
| adjuvant numeracy | #1 |
| fluorouracilinduced stomatitis | #1 |
| pilot trial hands | #1 |
| sae δ − | #1 |
| nonhormonal agents | #1 |
| recommendation prevention | #1 |
| − fsfi | #1 |
| therapeutic targets cipn | #1 |
| lignans 6 weeks | #1 |
| pain chemotherapy | #1 |
| aimss life | #1 |
| chemotherapy treatment chemotherapy | #1 |
| score baseline values | #1 |
| patients physical examinations | #1 |
| life study arms | #1 |
| pilot trials efficacy | #1 |
| taxane treatment development | #1 |
| paclitaxel weekly cryotherapy | #1 |
| women inadequate control | #1 |
| treatments modalities | #1 |
| peripheral neuropathy | #1 |
| gas menopause patient | #1 |
| cyclohexanols female | #1 |
| prevention cipn | #1 |
| fluoxetine hot | #1 |
| lymphedema incidence intervention | #1 |
| cipn20 data | #1 |
| tingling | #1 |
| toxicity agent | #1 |
| stellate ganglion block | #1 |
| chamomile mouthwash | #1 |
| median δ qs | #1 |
| vitamin cipn | #1 |
| benefit 5fu | #1 |
| cachexia cyproheptadine | #1 |
| estimated benefit dfs | #1 |
| treatment attribution | #1 |
| n01c9 | #1 |
| revisitation doc | #1 |
| oestrogen hot flashes | #1 |
| chemotherapy response rates | #1 |
| flashes breast | #1 |
| cipnmethodspatients | #1 |
| cyproheptadine appetite | #1 |
| n06ca | #1 |
| qolconclusionsthe | #1 |
| weeks hot | #1 |
| inadequate hot | #1 |
| gabapentin antidepressant | #1 |
| treatment hot flashes | #1 |
| nonfluid weight gain | #1 |
| data hot | #1 |
| accru trial | #1 |
| weight megestrol acetate | #1 |
| 1year survival trials | #1 |
| combination chemotherapy hec | #1 |
| background hot | #1 |
| aes relatedness | #1 |
| discrepancies women | #1 |
| patients highdose interferon | #1 |
| antidepressants gabapentin | #1 |
| joints syndrome | #1 |
| intervention leap | #1 |
| hot flashes weeks | #1 |
| toxicity gabapentin | #1 |
| eortc cipn20 | #1 |
| established cipn | #1 |
| paresthesia peripheral | #1 |
| hot flash relief | #1 |
| illness neuropathic symptoms | #1 |
| anorexia appetite | #1 |
| aminobutyric acid hec | #1 |
| doubleblinded manner | #1 |
| oral cryotherapy | #1 |
| prognosis items | #1 |
| ctcae grade | #1 |
| 1 month appetite | #1 |
| doxepin mouthwash patients | #1 |
| safety progestational agents | #1 |
| records adult patients | #1 |
| pharmacologic therapeutics | #1 |
| antiemetic prescribing practices | #1 |
| hot flashes treatment | #1 |
| reducing hot | #1 |
| accru study ru221408i | #1 |
| burning pain | #1 |
| hot flashes day | #1 |
| bothersome hot flashes | #1 |
| uncertain gbu | #1 |
| olanzapine arm emesis | #1 |
| fourth treatment week | #1 |
| cipn development severity | #1 |
| cipn data | #1 |
| alopecia ocular toxicity | #1 |
| n08ca patients | #1 |
| patients placebo pellet | #1 |
| agents humans clinicians | #1 |
| hormonal ablation andropause | #1 |
| mouthwash placebo | #1 |
| flashes pilot | #1 |
| bothersome hot | #1 |
| cryotherapy hands | #1 |
| pilot trials venlafaxine | #1 |
| cinv neoplasms vomiting | #1 |
| compounded topical gel | #1 |
| acceptability ssc device | #1 |
| 8week observation period | #1 |
| nonfluid | #1 |
| effects cipn | #1 |
| hot flashes women | #1 |
| numbness hands | #1 |
| patientcompleted questionnaires | #1 |
| flashes gabapentin | #1 |
| dmc mutations | #1 |
| cancer hot | #1 |
| eortc qlqcipn20 instrument | #1 |
| effects limited efficacy | #1 |
| hot flash | #1 |
| placebo anecdotal observations | #1 |
| gabapentin hot flashes | #1 |
| flash scores | #1 |
| hot flashes gabapentin | #1 |
| day cisplatin therapy | #1 |
| hot flash control | #1 |
| understanding potential benefits | #1 |
| isae | #1 |
| active nonhormonal | #1 |
| flaxseed bar | #1 |
| ulabtka hfs | #1 |
| recommended colorectal | #1 |
| methylphenidate cancer patients | #1 |
| patients cancer anorexia | #1 |
| reduction hot | #1 |
| authors 115 patients | #1 |
| a151408 study data | #1 |
| physical consequences cipn | #1 |
| points doxepin | #1 |
| women 65 day | #1 |
| nsclc response rate | #1 |
| anecdotal observations | #1 |
| cipn paps | #1 |
| points diphenhydramine | #1 |
| patients spray product | #1 |
| prevent oxaliplatin | #1 |
| oil nasal | #1 |
| middle aged minocycline | #1 |
| cipn clinical trial | #1 |
| prevention induced cipn | #1 |
| women megestrol acetate | #1 |
| overview crci | #1 |
| natural postural instability | #1 |
| oncologists prognostic | #1 |
| symptoms feet | #1 |
| extreme phenotyping | #1 |
| megestrol acetate patients | #1 |
| outcomes study points | #1 |
| cipn trials | #1 |
| oral mucosa study | #1 |
| nociceptors putative mechanism | #1 |
| papsmethodspatients | #1 |
| prtmethodsdata | #1 |
| nonfluid bodyweights | #1 |
| darbepoetin alfa head | #1 |
| oncologists competence | #1 |
| education lymphedema education | #1 |
| 2 study arms | #1 |
| preliminary promising data | #1 |
| time publication attitude | #1 |
| bridging editorial | #1 |
| snv rs9657362 | #1 |
| feet oxaliplatin | #1 |
| cipn agents | #1 |
| cancerassociated anorexia cachexia | #1 |
| education lymphedema prevention | #1 |
| cipn adult | #1 |
| male megestrol megestrol | #1 |
| paclitaxel polyneuropathy | #1 |
| digital melt curve | #1 |
| pilot evaluation | #1 |
| rom leap | #1 |
| subcutaneous testosterone improvements | #1 |
| managing hot | #1 |
| randomized study lymphedema | #1 |
| ganglion surveys humans | #1 |
| rs9657362 previous study | #1 |
| 65 day | #1 |
| prominent clinical problem | #1 |
| device 5 weeks | #1 |
| neuropathic symptoms breast | #1 |
| fsfi 95 | #1 |
| attribution treatment | #1 |
| week tamoxifen | #1 |
| antiserotonergic drug | #1 |
| highdose melphalan intervention | #1 |
| 22 nonestrogenic management | #1 |
| tools oncologists | #1 |
| supportive cytotoxic chemotherapy | #1 |
| gait testing patients | #1 |
| hot flash score | #1 |
| subsequent chemotherapy cycles | #1 |
| placebo arms percentage | #1 |
| adam vte | #1 |
| doxepin mouthwash | #1 |
| cipn postural control | #1 |
| regional hypothermia burden | #1 |
| pilot trials citalopram | #1 |
| magnesium camg | #1 |
| 20 data patients | #1 |
| sensory neuropathy symptoms | #1 |
| 12 months anticoagulation | #1 |
| cachexia carcinoma life | #1 |
| crc patients 95 | #1 |
| uncertain gbu gbu | #1 |
| dmc samples | #1 |
| patients 25 micrograms | #1 |
| acetate dexamethasone | #1 |
| patients subcutaneous testosterone | #1 |
| suggestion pregabalin | #1 |
| treatment hot | #1 |
| cipn phase iii | #1 |
| week hot | #1 |
| hours nighttime sleep | #1 |
| arhgef10 cipn | #1 |
| life qlqcipn20 | #1 |
| based chemotherapy isae | #1 |
| topical keratolytic | #1 |
| hot flashes quality | #1 |
| patientreported outcomes balance | #1 |
| gabapentin hot | #1 |
| topical cannabinoids | #1 |
| increased difficulty patients | #1 |
| deprivation therapy patients | #1 |
| anecdotal observations gabapentin | #1 |
| or1 year patients | #1 |
| n08ca | #1 |
| neuropathy randomized | #1 |
| centrally active agent | #1 |
| accru study | #1 |
| managing hot flashes | #1 |
| neoplasms climacteric | #1 |
| symptoms cipn | #1 |
| vaginal dehydroepiandrosterone | #1 |
| treating hot | #1 |
| cachexia megestrol | #1 |
| oral cryotherapy management | #1 |
| loe prevention | #1 |
| oncology providers crci | #1 |
| mouthwash diphenhydramine | #1 |
| recurrences clinical histories | #1 |
| neoplasms placebos | #1 |
| alleviating hot | #1 |
| symptoms hormone deprivation | #1 |
| placebo drowsiness | #1 |
| fosaprepitant isae | #1 |
| sensory subscale | #1 |
| benefit fluoxetine | #1 |
| flashes prostate | #1 |
| hot flash activity | #1 |
| 30 points 95 | #1 |
| treating institution intervention | #1 |
| prestudy hypothesis | #1 |
| placebo arm gabapentin | #1 |
| ru221408i | #1 |
| acetate appetite | #1 |
| evidence cipn | #1 |
| association arhgef10 | #1 |
| ssc device prototype | #1 |
| acetate doses | #1 |
| cancers prevalence | #1 |
| nonhormonal hot | #1 |
| arthralgia breast life | #1 |
| oxybutynin doses | #1 |
| n08cb | #1 |
| oral cryotherapy prevention | #1 |
| 5 methylphenidate | #1 |
| diseases pilot | #1 |
| balance patientreported outcomes | #1 |
| data clinical histories | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| hormone deprivation cancer | #1 |
| flashes quality | #1 |
| qolresultsfrom | #1 |
| induced neurotoxicity oct2 | #1 |
| purposehot flashes | #1 |
| nonestrogenic management | #1 |
| postsurgical neuropathic pain | #1 |
| cvte rivaroxaban | #1 |
| study stool samples | #1 |
| infliximab cancer | #1 |
| developed mucositis | #1 |
| suggested gabapentin | #1 |
| hot flash data | #1 |
| topic rectum surveys | #1 |
| isae anthracycline | #1 |
| disease patient factors | #1 |
| hot flash scores | #1 |
| therapy hot | #1 |
| hot flashes patients | #1 |
| flash therapies | #1 |
| patients ulabtka | #1 |
| auc cryotherapy | #1 |
| positive indication prognosis | #1 |
| agents cipn | #1 |
| prominent toxicity | #1 |
| motor subscales | #1 |
| acetate hot | #1 |
| response relationship odc | #1 |
| paclitaxel acute | #1 |
| ocular ice | #1 |
| adjuvant numeracy calculators | #1 |
| 81 patients patients | #1 |
| cipnsummarythere | #1 |
| receiving fluorouracil | #1 |
| life cipn | #1 |
| stomatitis scores | #1 |
| patients dosing guidelines | #1 |
| compliance institutional guideline | #1 |
| weight loss investigation | #1 |
| baseline week gabapentin | #1 |
| phytotherapy vitamin | #1 |
| relatedness treatment arms | #1 |
| 95 increased difficulty | #1 |
| qlq cipn20 | #1 |
| minocycline cipn | #1 |
| tested interventions lymphedema | #1 |
| weeks hot flashes | #1 |
| toxicity prospective trial | #1 |
| paps fatigue | #1 |
| drowsiness unpleasant taste | #1 |
| patients nasal vestibulitis | #1 |
| items uncertain gbu | #1 |
| extensive animal data | #1 |
| antidepressant gabapentin | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| eortc cipn | #1 |
| tpn longterm survival | #1 |
| 95 doxepin mouthwash | #1 |
| lidocaine antacid | #1 |
| tingling numbness | #1 |
| oxybutynin hot flashes | #1 |
| cachexia trial | #1 |
| lymphedemafree rates groups | #1 |
| single snv rs9657362 | #1 |
| antidepressive agents gamma | #1 |
| difficulty neuropathic pain | #1 |
| agents antihypertensive agents | #1 |
| initiation tpn | #1 |
| placebo 15 glutathione | #1 |
| alliance n08c1 | #1 |
| hfs trial | #1 |
| aps paclitaxel | #1 |
| isae patients | #1 |
| head therapeutic equivalency | #1 |
| n08c1 | #1 |
| topical cannabinoids patients | #1 |
| studies cyproheptadine | #1 |
| complete response authors | #1 |
| conducted studies hrt | #1 |
| ncctg trial n06ca | #1 |
| acute symptoms cycle | #1 |
| numerical analogue scale | #1 |
| vte recurrence enoxaparin | #1 |
| underdescribing | #1 |
| cachexia dexamethasone | #1 |
| inadequate control antidepressant | #1 |
| cipn nervous diseases | #1 |
| nonhormonal | #1 |
| management hot flashes | #1 |
| paclitaxel coasting phenomenon | #1 |
| chemotherapy neuropathy | #1 |
| cipn methods | #1 |
| rs17683288 | #1 |
| tpn initiation death | #1 |
| grade peripheral neuropathy | #1 |
| 137 patients cycle | #1 |
| ncctg n08c1 | #1 |
| 2007 guidelines suggestion | #1 |
| placebo oral mucositis | #1 |
| underdescribers weeks | #1 |
| postural instability chemotherapy | #1 |
| survival tpn initiation | #1 |
| alliance trial | #1 |
| impaired postural control | #1 |
| dronabinol combination | #1 |
| bakplo symptoms | #1 |
| hot flashes | #1 |
| suggestion toxicity | #1 |
| bortezomib alters | #1 |
| purpose hot | #1 |
| 5fu adjuvant | #1 |
| glutamine toxicity | #1 |
| altered sensory organization | #1 |
| effects hot flashes | #1 |
| underdescribers | #1 |
| hfs ulabtka | #1 |
| acute pain syndrome | #1 |
| pregabalin paps | #1 |
| cytotoxic chemotherapy supportive | #1 |
| mascc isoo evidence | #1 |
| hormone deprivation symptoms | #1 |
| compliance institutional guidelines | #1 |
| trial n00cb | #1 |
| judicious tpn | #1 |
| slight appetite stimulation | #1 |
| acetate versus | #1 |
| cipn topical gel | #1 |
| individuals cipn | #1 |
| toxicity anecdotal observations | #1 |
| discrepancies clinicians assessment | #1 |
| n08cb alliance | #1 |
| modalities cancer patients | #1 |
| 95 neuropathic pain | #1 |
| cipn20 sensory | #1 |
| purposepaclitaxel | #1 |
| management hot | #1 |
| baseline prognosis | #1 |
| nonhormonal agent | #1 |
| flashes week | #1 |
| flashes prospective | #1 |
| 5fuinduced ocular toxicity | #1 |
| institutional guidelines patients | #1 |
| nonfluid weight | #1 |
| iii double | #1 |
| udi scores baseline | #1 |
| doxepin mouthwash placebo | #1 |
| bakplo placebo | #1 |
| dmc assay | #1 |
| duloxetine response | #1 |
| tpn female services | #1 |
| fractures infertility | #1 |
| placebo 30 points | #1 |
| lymphedemafree rates | #1 |
| flash score | #1 |
| baseline week followup | #1 |
| items positive indication | #1 |
| burden alopecia | #1 |
| alleviate hot | #1 |
| humans ganglion surveys | #1 |
| lymphedema prevention education | #1 |
| newer antidepressants | #1 |
| survivors genitourinary syndrome | #1 |
| cipn20 questionnaire | #1 |
| cancerrelated fatigue interventions | #1 |
| megestrol acetate | #1 |
| rest psychostimulants | #1 |
| female services tpn | #1 |
| individuals impaired balance | #1 |
| nasal vestibulitis | #1 |
| isae data | #1 |
| difference cipn20 scores | #1 |
| ambulatory patients opioids | #1 |
| suggestion oral cryotherapy | #1 |
| pilot citalopram | #2 |
| day baseline week | #2 |
| mometasone cream | #2 |
| hot flashes efficacy | #2 |
| cachexia pentoxifylline | #2 |
| aprepitan | #2 |
| subsequent mucositis | #2 |
| dosing zoledronic | #2 |
| cycle folfox | #2 |
| infliximab docetaxel | #2 |
| cipn cohort | #2 |
| weight concerns 26 | #2 |
| 80 anorexia | #2 |
| npy levels groups | #2 |
| design considerations recommendations | #2 |
| treatment minority smokers | #2 |
| evaluating venlafaxine | #2 |
| nutrition scores 95 | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| smokers nicotine inhaler | #2 |
| scrambler therapy management | #2 |
| treatment week placebo | #2 |
| pregabalin arms | #2 |
| ncctg n10c1 | #2 |
| 95 indirect estimates | #2 |
| paclitaxel induced | #2 |
| 120000 epoetin alfa | #2 |
| evaluate weight | #2 |
| tamoxifen percentage reduction | #2 |
| tamoxifen metabolism evidence | #2 |
| antidepressant hot flashes | #2 |
| trial acetate doses | #2 |
| dhea vaginal symptoms | #2 |
| reducing chemotherapy | #2 |
| descriptive manner | #2 |
| target doses placebo | #2 |
| cisplatin polymerase inhibitors | #2 |
| kps nutrition score | #2 |
| n01c4 | #2 |
| chemotherapyassociated anemia caa | #2 |
| fatigue improvement methylphenidate | #2 |
| treatment cycles cycle | #2 |
| vitamin hot | #2 |
| 34—vitamin | #2 |
| aprepitant 4 weeks | #2 |
| treatment arm mmf | #2 |
| phytogenic female humans | #2 |
| study arms conclusions | #2 |
| hot flashes pregabalin | #2 |
| desipramine hot flashes | #2 |
| anemia caa | #2 |
| folfox symptoms | #2 |
| starting tamoxifen women | #2 |
| treatment smoking abstinence | #2 |
| receiving megestrol | #2 |
| experience hot flashes | #2 |
| leucovorin women | #2 |
| treatment breakthrough cinv | #2 |
| trials newer antidepressants | #2 |
| placebo breast radiotherapy | #2 |
| time randomized study | #2 |
| epoetin alfa 40000 | #2 |
| nutrition scores physicians | #2 |
| efficacy scrambler therapy | #2 |
| women rom | #2 |
| 120 arm | #2 |
| longitudinal studies postmenopause | #2 |
| tingling shooting | #2 |
| flashes citalopram | #2 |
| ductal mometasone furoate | #2 |
| dhea 4 weeks | #2 |
| ctcae differences | #2 |
| study arms | #2 |
| cycle chronic neurotoxicity | #2 |
| anthrapyrazoles piroxantrone | #2 |
| type chemotherapy drug | #2 |
| humans citalopram cyclohexanols | #2 |
| acknowledged loss | #2 |
| 5fubased chemotherapy mucositis | #2 |
| treating chemotherapy | #2 |
| management genitourinary symptoms | #2 |
| pruritus pros | #2 |
| oxybutynin doses placebo | #2 |
| hf frequency placebo | #2 |
| lvef 1000 | #2 |
| adjuvant 5fu models | #2 |
| patients monthly intervals | #2 |
| control arms rate | #2 |
| placebo bar | #2 |
| patients treating institution | #2 |
| inadequate benefit | #2 |
| appetite cachexia | #2 |
| venlafaxine treatment 75 | #2 |
| arms conclusions | #2 |
| sdt2 | #2 |
| 16 hemoccult | #2 |
| appetite dissent disputes | #2 |
| citalopram cyclohexanols humans | #2 |
| flash studies | #2 |
| nutrition score disagreement | #2 |
| dronabinoltreated patients | #2 |
| average stomatitis sex | #2 |
| reduce hot | #2 |
| vte recurrence dalteparin | #2 |
| 1 oral megestrol | #2 |
| skindex16 ctcae | #2 |
| global impression life | #2 |
| singleagent megestrol acetate | #2 |
| anabolic corticosteroid | #2 |
| appearing pilot data | #2 |
| patients black cohosh | #2 |
| trial suggestion | #2 |
| paclitaxel chronic neuropathy | #2 |
| glutathione prevention | #2 |
| stage disease 5fu | #2 |
| allopurinol mouthwash | #2 |
| postmenopausal women previous | #2 |
| 979254 | #2 |
| infliximab 5 day | #2 |
| oxaliplatin hands | #2 |
| hot flashes citalopram | #2 |
| cipn cancer survivors | #2 |
| declining qol | #2 |
| 40k arm 120000 | #2 |
| postural instability individuals | #2 |
| flashes placebo | #2 |
| shark cartilage placebo | #2 |
| cold items 71 | #2 |
| patients 120k arm | #2 |
| patients olanzapine arm | #2 |
| treatment baseline week | #2 |
| scrambler | #2 |
| neuropathy caused | #2 |
| placebo arms women | #2 |
| treatment target doses | #2 |
| cachexia acetate | #2 |
| sunscreen arms | #2 |
| stomatitis women | #2 |
| hot flash frequencies | #2 |
| alternative treatment regimen | #2 |
| folfox auc analysis | #2 |
| subject global impression | #2 |
| alliance folfox | #2 |
| cohosh treatment | #2 |
| local antineoplastic agents | #2 |
| placebo combination therapy | #2 |
| infertility ovarian failure | #2 |
| cipn antineoplastic agents | #2 |
| ecog nutrition score | #2 |
| breast cancer venlafaxine | #2 |
| pregabalin treatments placebo | #2 |
| scrambler therapy tens | #2 |
| treatment alterations | #2 |
| hot flashes aprepitant | #2 |
| nonestrogenic hot | #2 |
| stat itching | #2 |
| 135±19 | #2 |
| patients chemotherapyassociated anemia | #2 |
| dalteparin lowest risk | #2 |
| mmf itching | #2 |
| weekly epoetin | #2 |
| outcome measures ctcae | #2 |
| therapy hot flashes | #2 |
| established chemotherapy | #2 |
| symptoms surveys | #2 |
| original report mometasone | #2 |
| dronabinol combination therapy | #2 |
| cipn primary outcomes | #2 |
| antidepressants hot | #2 |
| females cessation treatment | #2 |
| anorexia severity | #2 |
| positive doseresponse | #2 |
| placebo oxybutynin doses | #2 |
| placebo hf frequency | #2 |
| 4 treatment weeks | #2 |
| day study week | #2 |
| patients cipn | #2 |
| oral megestrol | #2 |
| week black cohosh | #2 |
| methylphenidate cancer | #2 |
| cipn cancer treatment | #2 |
| cipn interventions | #2 |
| decreasing stomatitis | #2 |
| neoplasms double | #2 |
| product hot flashes | #2 |
| 46 adenomas 1 | #2 |
| previous hot flashes | #2 |
| scrambler therapy treatment | #2 |
| clinical trials n9741 | #2 |
| receive parenteral | #2 |
| anabolic corticosteroid treatment | #2 |
| treatment aprepitant | #2 |
| cipn | #2 |
| real real patients | #2 |
| cck8 anorexia severity | #2 |
| study n08cb alliance | #2 |
| kps nutrition scores | #2 |
| duloxetine hydrochloride humans | #2 |
| 7 control arms | #2 |
| life aimss | #2 |
| historic controls npy | #2 |
| time toxt approach | #2 |
| lmwh arms 7 | #2 |
| monthly intervals appetite | #2 |
| autonomic scales | #2 |
| oral iron 46 | #2 |
| disagreement patients | #2 |
| hot flash diary | #2 |
| symptoms skin toxicity | #2 |
| hemoccultsensa sdt1 | #2 |
| ≤ moderate correlations | #2 |
| pregabalin hot flashes | #2 |
| citalopram hot flashes | #2 |
| piroxantrone women | #2 |
| nonhormonal management | #2 |
| fsfi score baseline | #2 |
| increased risk cipn | #2 |
| gabapentin symptoms | #2 |
| natural paps | #2 |
| study arms tetracycline | #2 |
| appetite improvement | #2 |
| 15 points 95 | #2 |
| patients adjuvant 5fu | #2 |
| provider assessed | #2 |
| numeracy prognosis | #2 |
| central cancer | #2 |
| vitamin hot flashes | #2 |
| cancerassociated anorexia | #2 |
| dexamethasone fluoxymesterone | #2 |
| oxybutynin women | #2 |
| moderate correlations ≤ | #2 |
| hot flash studies | #2 |
| differences mometasone | #2 |
| 95 oral placebo | #2 |
| hot flash management | #2 |
| life scrambler therapy | #2 |
| appetite dissent | #2 |
| symptomatic cipn | #2 |
| lamotrigine neuropathic symptoms | #2 |
| colonoscopically normal patients | #2 |
| illness tetracycline egfr | #2 |
| sdt1 hemoccult | #2 |
| n03cb | #2 |
| intermediate term efficacy | #2 |
| surveys repeated measures | #2 |
| improvement hot | #2 |
| placebo vaginal dryness | #2 |
| megestrol acetate dexamethasone | #2 |
| coumarin placebo | #2 |
| pain ≥4 10 | #2 |
| postchemotherapy rheumatism | #2 |
| locoregional event | #2 |
| anabolic corticosteroid appetite | #2 |
| 40000 40k arm | #2 |
| induced peripheral neuropathy | #2 |
| detection dna markers | #2 |
| worse survivorship | #2 |
| tens 2 weeks | #2 |
| vte recurrence doacs | #2 |
| pilocarpine arms | #2 |
| eortc qlqcipn20 | #2 |
| weekly hf score | #2 |
| cipn cases | #2 |
| magnesium oxaliplatin | #2 |
| rash incidence severity | #2 |
| coriat | #2 |
| 3 months bupropion | #2 |
| flash diary | #2 |
| life cancerrelated fatigue | #2 |
| toxicity profiles time | #2 |
| supplementary n03cb | #2 |
| guidelines recommendation | #2 |
| skindex16 itching | #2 |
| 75 49 venlafaxine | #2 |
| time toxt analysis | #2 |
| conceppt | #2 |
| patients shark cartilage | #2 |
| poor qol 95 | #2 |
| cancerassociated wasting | #2 |
| docetaxel serum concentrations | #2 |
| tingling patients | #2 |
| 01 mmf | #2 |
| daily mmf radiotherapy | #2 |
| conclusions sunscreen | #2 |
| tamoxifen medications | #2 |
| time ncctg alliance | #2 |
| prevent paclitaxel | #2 |
| dna markers participants | #2 |
| substantial hot flashes | #2 |
| tens global impression | #2 |
| hemoccultsensa sensitivity | #2 |
| 120k arm | #2 |
| guaninemethyltransferase | #2 |
| advancedstage cancer | #2 |
| mometasone time | #2 |
| 432 smokers treatment | #2 |
| newer antidepressants trials | #2 |
| dermatitis symptom evolution | #2 |
| patients difluoromethylornithine | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| mometasone surveys | #2 |
| feet 18 months | #2 |
| cipn peripheral neuropathy | #2 |
| suggested agents | #2 |
| anorexia antineoplastic | #2 |
| single snv | #2 |
| 5fuinduced mucositis | #2 |
| incidence severity stomatitis | #2 |
| women stomatitis | #2 |
| mucositis 5fubased chemotherapy | #2 |
| predictors disagreement | #2 |
| tamoxifenassociated hot flashes | #2 |
| egfr inhibitor tetracycline | #2 |
| hot flashes humans | #2 |
| induced arthralgias | #2 |
| screenrelevant neoplasms | #2 |
| indirect comparison apixaban | #2 |
| peripheral neuropathy cipn | #2 |
| 16 sdt2 | #2 |
| ferric gluconate darbepoetin | #2 |
| humans postmenopause pregabalin | #2 |
| preventive therapies cipn | #2 |
| topical aged antimetabolites | #2 |
| patient‐physician disagreement | #2 |
| rcts preventive therapies | #2 |
| iii randomized | #2 |
| hemoccultsensa hemoccult | #2 |
| venlafaxine control | #2 |
| women hot flashes | #2 |
| neuropathy cipn | #2 |
| 120k arm patients | #2 |
| questionnaires antineoplastic agents | #2 |
| manuscript “use | #2 |
| placebo situ carcinoma | #2 |
| anthraquinones agents breast | #2 |
| life venlafaxine | #2 |
| cipn paclitaxel | #2 |
| fluoxymesterone treatment | #2 |
| pilocarpine vaginal | #2 |
| middle aged survivors | #2 |
| failure prior chemotherapy | #2 |
| bupropion nicotine inhaler | #2 |
| glutamine placebo preparation | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| prevent radiation | #2 |
| week breast cancer | #2 |
| randomized receive | #2 |
| levetiracetam 4 weeks | #2 |
| thiophenes treatment life | #2 |
| hot flashes data | #2 |
| months randomized | #2 |
| venlafaxine gabapentin | #2 |
| gabapentin 4 weeks | #2 |
| cachexia decision | #2 |
| 150 groups patients | #2 |
| irox folfox auc | #2 |
| circulating concentrations npy | #2 |
| week baseline week | #2 |
| qol crc | #2 |
| patients 40k arm | #2 |
| woman quality | #2 |
| “use vitamin | #2 |
| intervention 18 months | #2 |
| life 4week intervention | #2 |
| neuropathy paclitaxel | #2 |
| day average pain | #2 |
| randomized study mometasone | #2 |
| study arms quality | #2 |
| patients oxybutynin doses | #2 |
| nonestrogenic therapies | #2 |
| scrambler therapy | #2 |
| clinically deficient fatigue | #2 |
| cpmp scrambler therapy | #2 |
| fosaprepitant patients | #2 |
| screenrelevant neoplasms 16 | #2 |
| life treatment weeks | #2 |
| life cipn20 | #2 |
| baseline week day | #2 |
| folfox alliance | #2 |
| ncctg trial | #2 |
| study treatment citalopram | #2 |
| induced peripheral | #2 |
| qol hb increment | #2 |
| hemoccultsensa sdt2 | #2 |
| disagreement increased risk | #2 |
| sensitivity cold items | #2 |
| detection screenrelevant neoplasms | #2 |
| patients daily mmf | #2 |
| trial baseline week | #2 |
| 108±11 | #2 |
| dronabinol versus | #2 |
| chronic chemotherapy | #2 |
| physicians kps | #2 |
| n06c4 | #2 |
| ctcae pruritus | #2 |
| cdf score | #2 |
| pa outcomes pros | #2 |
| 800 liquid suspension | #2 |
| evaluating gabapentin | #2 |
| hot flashes bupropion | #2 |
| cipn clinical | #2 |
| shark cartilage patients | #2 |
| acttionconsortium | #2 |
| folfox auc p0·0001 | #2 |
| shark cartilage product | #2 |
| hot flash trials | #2 |
| lessons cipn | #2 |
| starting tamoxifen | #2 |
| n0993 | #2 |
| patients receiving fluorouracil | #2 |
| sdt2 sdt1 | #2 |
| tetracycline rash incidence | #2 |
| data gabapentin | #2 |
| depomedroxyprogesterone | #2 |
| palliative communications | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| cipn prevention trials | #2 |
| injections hot flashes | #2 |
| breakthrough cinv | #2 |
| hemoccultsensa detection | #2 |
| life illness tetracycline | #2 |
| stomatitis sex | #2 |
| advanced cancer anorexia | #2 |
| hot flash quality | #2 |
| oxaliplatin doses trends | #2 |
| trials suggested | #2 |
| participants 3 stools | #2 |
| topic estrogen | #2 |
| nicotine inhaler bupropion | #2 |
| life venlafaxine hydrochloride | #2 |
| cipn20 scores | #2 |
| npy anorexia cholecystokinin | #2 |
| 49 venlafaxine | #2 |
| 46 screenrelevant neoplasms | #2 |
| standard arm rate | #2 |
| cipn20 factor analysis | #2 |
| sulfate prevent | #2 |
| older age bupropion | #2 |
| sdt2 hemoccult | #2 |
| versus megestrol | #2 |
| stat erythema | #2 |
| 14 hot flashes | #2 |
| lmwh arms | #2 |
| conclusions original report | #2 |
| pilocarpine vaginal dryness | #2 |
| real patients treatment | #2 |
| prevalence weight concerns | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| original report time | #2 |
| placebo pregabalin treatments | #2 |
| doses megestrol | #2 |
| data relative benefits | #2 |
| survival 3915 patients | #2 |
| improvement hot flashes | #2 |
| 40k arm | #2 |
| usual breathing | #2 |
| chemotherapy peripheral neuropathy | #2 |
| cyproheptadine patients | #3 |
| alfa compared | #3 |
| upfront arm | #3 |
| 95 40 points | #3 |
| upfront treatment arm | #3 |
| carboplatin gwas | #3 |
| baseline hot | #3 |
| neuropathy trials | #3 |
| study population mcbdr | #3 |
| blind trial | #3 |
| chlorhexidine mouthwash | #3 |
| toxicities selfreport | #3 |
| recommendations dietary counseling | #3 |
| chemotherapy gabapentin | #3 |
| cipn ctpm | #3 |
| patients cancerassociated wasting | #3 |
| n08cx | #3 |
| mouthwash patients | #3 |
| stomatitis sucralfate | #3 |
| mfsisf 4 weeks | #3 |
| canada collaborative effort | #3 |
| genetic predictors cipn | #3 |
| cancer patients drugs | #3 |
| mpa single dose | #3 |
| fasting chemotherapy | #3 |
| dalteparin vte | #3 |
| survival epa | #3 |
| drug toxicity patients | #3 |
| neurotoxic chemotherapy cipn | #3 |
| paps scores | #3 |
| genetic predictors paclitaxel | #3 |
| “use | #3 |
| female gabapentin | #3 |
| life hospice patients | #3 |
| snv charcotmarietooth disease | #3 |
| asco guideline management | #3 |
| egfr inhibitor patients | #3 |
| cmt gene | #3 |
| interventions cancerrelated fatigue | #3 |
| bacterial agents life | #3 |
| 20 calories | #3 |
| evidence prostate adenocarcinoma | #3 |
| intravenous calcium magnesium | #3 |
| purposeoxaliplatin | #3 |
| ssc device | #3 |
| shooting burning pain | #3 |
| patient completed | #3 |
| hgpin chemoprevention trial | #3 |
| vitamin prevention | #3 |
| physiologic pilot | #3 |
| purposefosaprepitant | #3 |
| iii controlled | #3 |
| completed diaries | #3 |
| qlqcipn20 scores | #3 |
| middle aged pilot | #3 |
| depression somnolence | #3 |
| bivariate construct | #3 |
| life antineoplastic agents | #3 |
| trials n9741 | #3 |
| 1 month cytokines | #3 |
| traditional ctcae | #3 |
| ctcae grades patients | #3 |
| cold items | #3 |
| 51 female age | #3 |
| oxaliplatinbased therapy | #3 |
| etanercept current trial | #3 |
| rash study arms | #3 |
| primary endpoint gwas | #3 |
| gwas mayo clinic | #3 |
| hormonal ablation | #3 |
| hot flashes placebo | #3 |
| receive placebo | #3 |
| oral megestrol acetate | #3 |
| trial bmd | #3 |
| patients scrambler therapy | #3 |
| sham acupuncture week | #3 |
| male megestrol | #3 |
| hot flashes trial | #3 |
| cipn cmtassociated genes | #3 |
| data ginseng | #3 |
| eventual sensory patients | #3 |
| ginseng crf | #3 |
| prevent epidermal | #3 |
| selfreport ctcae grading | #3 |
| cmt genes oxaliplatin | #3 |
| delayed zoledronic | #3 |
| genetic factors patients | #3 |
| advanced cancer standard | #3 |
| patients baseline week | #3 |
| repeated measures analyses | #3 |
| fluoxetine arm | #3 |
| questionnaires syndrome paclitaxel | #3 |
| starting letrozole | #3 |
| controlled double | #3 |
| n08ca n08cb study | #3 |
| methodologic lessons | #3 |
| dhea hot flashes | #3 |
| week venlafaxine therapy | #3 |
| baseline treatment day | #3 |
| gabapentin management | #3 |
| experts cipn | #3 |
| centric decision | #3 |
| eightyone randomized women | #3 |
| 3 weeks 80k | #3 |
| cachexia decision humans | #3 |
| mastectomy rates | #3 |
| thromboembolism secondary | #3 |
| patients cyproheptadine | #3 |
| patients upfront arm | #3 |
| classic sums | #3 |
| rash symptoms | #3 |
| patients chemotherapy cycle | #3 |
| delayed treatment arm | #3 |
| pts stage iii | #3 |
| toxicity agents | #3 |
| cvte | #3 |
| qlqcipn20 traditional ctcae | #3 |
| mucositis scores | #3 |
| neoplasms vomiting | #3 |
| patients antiemetic | #3 |
| n05c4 | #3 |
| months bupropion | #3 |
| relationship numbness | #3 |
| follow fsfi | #3 |
| 10 weeks therapy | #3 |
| study antidepressive agents | #3 |
| cipn n08cx population | #3 |
| placebo breast | #3 |
| average severity | #3 |
| epoetin alfa hgb | #3 |
| epoetintreated patients | #3 |
| ctpm experts | #3 |
| rash conclusions | #3 |
| oxaliplatin primary endpoint | #3 |
| hands burning pain | #3 |
| general subscale mfsisf | #3 |
| snv cmtassociated genes | #3 |
| placebo prostate adenocarcinoma | #3 |
| survival cancerassociated wasting | #3 |
| ≤−20 | #3 |
| anorexia anorexia appetite | #3 |
| inhibitorinduced rash | #3 |
| chronic neuropathy patients | #3 |
| life dronabinol | #3 |
| pilot evaluation gabapentin | #3 |
| treatment bother | #3 |
| patients lidocaine patch | #3 |
| relationship response rate | #3 |
| qol placebotreated patients | #3 |
| topic mayo clinic | #3 |
| neurotoxic chemotherapies | #3 |
| combinationtreated arms survival | #3 |
| preventing peripheral | #3 |
| subcutaneous weekly | #3 |
| crossover methodology | #3 |
| numeracy patients | #3 |
| paps scores dose | #3 |
| 95 udi | #3 |
| osteoporosis osteopenia letrozole | #3 |
| qlqcipn20 | #3 |
| cipn snv | #3 |
| neuropathy chemotherapy | #3 |
| weekly arm differences | #3 |
| patients paps scores | #3 |
| 40000 units | #3 |
| apixaban lowest risk | #3 |
| week chemotherapy dose | #3 |
| oncology colorectal | #3 |
| mcbdr primary endpoint | #3 |
| controls singleton snv | #3 |
| egfr inhibitorinduced rash | #3 |
| corticosteroid medications | #3 |
| cyclohexanecarboxylic acids | #3 |
| hemoccultsensa | #3 |
| methylphenidate patients | #3 |
| chemotherapyassociated anemia | #3 |
| epa combinationtreated arms | #3 |
| bit hands | #3 |
| chemotherapy‐associated anemia | #3 |
| incurable cancers | #3 |
| longitudinal adverse | #3 |
| real day | #3 |
| n03cc | #3 |
| pilot trial pregabalin | #3 |
| ctcae pros | #3 |
| clonidine randomized trials | #3 |
| median δ | #3 |
| burning pain patients | #3 |
| management cancer cachexia | #3 |
| acetate treated | #3 |
| epoetintreated patients incidence | #3 |
| hgb rbc transfusions | #3 |
| chemotherapy induced | #3 |
| topical ceramides | #3 |
| asco surveillance | #3 |
| pros differences | #3 |
| data pilot trials | #3 |
| paps dose | #3 |
| oxaliplatin cipn | #3 |
| chemotherapy increases | #3 |
| measures peripheral | #3 |
| ” numbness | #3 |
| mcbdr | #3 |
| ctcae grading arms | #3 |
| cipn mcbdr population | #3 |
| acute neuropathy | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| iii evaluation | #3 |
| cipn biological targets | #3 |
| rash prevention | #3 |
| life eortc qlq | #3 |
| epoetintreated patients study | #3 |
| tamoxifen fluoxetine | #3 |
| qol hgb | #3 |
| tingling burning pain | #3 |
| cmtassociated genes | #3 |
| oxaliplatininduced neuropathy | #3 |
| minocycline prevention | #3 |
| projects prospective | #3 |
| aminobutyric acid gabapentin | #3 |
| feet 15 | #3 |
| prophylactic tetracycline | #3 |
| baseline general subscale | #3 |
| combinationtreated arms | #3 |
| n08ca paclitaxel | #3 |
| undergoing androgen ablation | #3 |
| survivors gsm | #3 |
| cartilage shark | #3 |
| flutamide hgpin | #3 |
| thirdline hormonal therapy | #3 |
| reported rash | #3 |
| experience greater | #3 |
| centrally active agents | #3 |
| trials newer | #3 |
| additional 4 weeks | #3 |
| frequency hot | #3 |
| hemoccult hemoccultsensa | #3 |
| ginseng arm | #3 |
| vaginal dhea | #3 |
| cipn evidence | #3 |
| radiation‐induced mucositis | #3 |
| placebo preparation | #3 |
| paced breathing | #4 |
| treatment ncctg | #4 |
| day paroxetine | #4 |
| anorectic cancer patients | #4 |
| calgb 70305 | #4 |
| hot flashes week | #4 |
| flaxseed placebo | #4 |
| loss syndrome | #4 |
| arm breast neoplasms | #4 |
| 6 months bupropion | #4 |
| risk reduction therapy | #4 |
| nonestrogenic | #4 |
| cachexia purpose | #4 |
| anorexia weight | #4 |
| rash incidence | #4 |
| placebo hot | #4 |
| oxybutynin placebo | #4 |
| controls imbalance | #4 |
| apr dex | #4 |
| baseline fatigue survival | #4 |
| oral cavity mucosa | #4 |
| nsclc trials | #4 |
| benefits adjuvant | #4 |
| odc odc activity | #4 |
| receive oral | #4 |
| cco guideline followup | #4 |
| outcomes olanzapine | #4 |
| colorectal cancer asco | #4 |
| bupropion 3 | #4 |
| hec cisplatin | #4 |
| backgroundhistorically | #4 |
| survivors hot | #4 |
| hfs quality | #4 |
| aged mouthwashes | #4 |
| intrapatient difference | #4 |
| weekly toxicity | #4 |
| hot flashes therapy | #4 |
| severity sexes | #4 |
| ais biomarkers | #4 |
| therapy oncologists | #4 |
| inhibitor induced | #4 |
| women greater toxicity | #4 |
| treatment cancer anorexia | #4 |
| measurable metastatic disease | #4 |
| odx ctx | #4 |
| appetite quality | #4 |
| suggested efficacy | #4 |
| predictors duloxetine response | #4 |
| doubleblind manner | #4 |
| control hot | #4 |
| doxepin female head | #4 |
| numbness toes | #4 |
| chemotherapy‐induced peripheral | #4 |
| to100 | #4 |
| ctx odx | #4 |
| gabapentin day | #4 |
| daily baseline | #4 |
| publication antiemetics humans | #4 |
| bupropion 3 months | #4 |
| doac dalteparin | #4 |
| cutaneous electrostimulation | #4 |
| appetite stimulation | #4 |
| 95 oral iron | #4 |
| breast medical oncologists | #4 |
| administration parp inhibitor | #4 |
| 900 dose | #4 |
| 1093 women | #4 |
| hgpin antineoplastic agents | #4 |
| fluorouracilbased chemotherapy | #4 |
| based chemotherapy severity | #4 |
| prominent problem | #4 |
| aimss | #4 |
| major doselimiting toxicity | #4 |
| cipn20 ctcae | #4 |
| single dose venlafaxine | #4 |
| egfr inhibitor rash | #4 |
| iron arm | #4 |
| guidelines oral | #4 |
| oral cryotherapy mucositis | #4 |
| placebo arms | #4 |
| toxt analysis | #4 |
| qol performance score | #4 |
| recommendation ctx | #4 |
| severe stomatitis leukopenia | #4 |
| tpn initiation | #4 |
| qol baseline fatigue | #4 |
| recommended endorsement | #4 |
| secondary vte prevention | #4 |
| weight loss syndrome | #4 |
| therapy aimss | #4 |
| additional meta analysis | #4 |
| general subscale | #4 |
| trpa1 cisplatin | #4 |
| 40000 | #4 |
| addition letrozole | #4 |
| symptoms individual patients | #4 |
| chronic neuropathy | #4 |
| odc activity mice | #4 |
| logistic regression incidence | #4 |
| vaginal assessment scale | #4 |
| 3915 patients | #4 |
| hemoccult | #4 |
| nonabsorbable antibiotic | #4 |
| parenteral iron | #4 |
| achievements ncctg | #4 |
| cancer acute vte | #4 |
| endorsed treatment | #4 |
| or1 year | #4 |
| flash frequency | #4 |
| anorexia cholecystokinin | #4 |
| surgery lymphedema | #4 |
| topic survivors | #4 |
| based chemotherapy women | #4 |
| rash study | #4 |
| dietician | #4 |
| mastectomy rates patients | #4 |
| followup surveillance protocol | #4 |
| crc cancer types | #5 |
| trial gabapentin | #5 |
| cachexia anorexia | #5 |
| difference control arm | #5 |
| colorectal cancer society | #5 |
| fiftynine percent | #5 |
| treating postmenopausal | #5 |
| 3 patients 4 | #5 |
| race ttr | #5 |
| odx | #5 |
| 5fu trials | #5 |
| nodal status grade | #5 |
| pain scores dose | #5 |
| neuropathic pain qol | #5 |
| appetite enhancement | #5 |
| cisplatin ganglia | #5 |
| 3 stools | #5 |
| mucositis caused | #5 |
| disputes female humans | #5 |
| numeracy online clinical | #5 |
| oxantrazole | #5 |
| trials cytotoxic chemotherapy | #5 |
| genetic quality life | #5 |
| kps ecog | #5 |
| ongoing clinical trial | #5 |
| questionnaires pregabalin | #5 |
| intravenous calcium | #5 |
| reduce chemotherapy | #5 |
| fluoxymesterone patients | #5 |
| acetate placebo | #5 |
| models ttr | #5 |
| physicians predictive ttr | #5 |
| cipn effects | #5 |
| reported hot | #5 |
| cyclohexanecarboxylic | #5 |
| iron oral | #5 |
| ajcc external validation | #5 |
| cipn participants | #5 |
| ttr variables | #5 |
| induced stomatitis | #5 |
| physicianreported | #5 |
| cancer survivors symptoms | #5 |
| impaired postural | #5 |
| subsets treatment benefits | #5 |
| agents basis | #5 |
| libido | #5 |
| groups leptin concentrations | #5 |
| acetate neoplasms | #5 |
| nutrition scores | #5 |
| death communication humans | #5 |
| cancer anorexia | #5 |
| combination electroacupuncture | #5 |
| cindices ajcc | #5 |
| acetate neoplasms quality | #5 |
| hb increment | #5 |
| progestational agent | #5 |
| cipnrelated symptoms | #5 |
| grade model estimates | #5 |
| major outcome measure | #5 |
| women 5fu | #5 |
| patient outcomes numeracy | #5 |
| sham real | #5 |
| neuropathy acute | #5 |
| receiving paclitaxel | #5 |
| ttr ajcc | #5 |
| aapro | #5 |
| trial developed | #5 |
| additional 8 weeks | #5 |
| mucositis allopurinol | #5 |
| patients lmwh injections | #5 |
| flashes data | #5 |
| rectal cancer surveillance | #5 |
| bone loss osteopenia | #5 |
| cipn numbness | #5 |
| postsurgical neuropathic | #5 |
| current trial patients | #5 |
| cumulative neurotoxicity | #5 |
| study dmc | #5 |
| life epa | #5 |
| neoplasms compared | #5 |
| crc cancers | #5 |
| tools numeracy | #5 |
| neuropeptide leptin | #5 |
| trial hot | #5 |
| medical oncology outpatients | #5 |
| higher drug doses | #5 |
| centrally active | #5 |
| epa supplement | #5 |
| treatment benefits sex | #5 |
| gabapentin trial | #5 |
| neoplasm diagnostic tests | #5 |
| editor manuscript | #5 |
| colorectal cancer surveillance | #5 |
| vasomotor hot flashes | #5 |
| ajcc tools | #5 |
| discontinuation aimss | #5 |
| trials lessons | #5 |
| digital melt | #5 |
| life lmwh | #5 |
| gabapentin patients | #5 |
| numeracy tools | #5 |
| ttr cindices | #5 |
| olanzapine arm | #5 |
| cancerrelated fatigue patients | #5 |
| ajcc version staging | #5 |
| fosaprepitant prevention | #5 |
| placebo exposed | #5 |
| nodal status stage | #5 |
| severity data | #6 |
| agents breast | #6 |
| paclitaxel peripheral neuropathy | #6 |
| wisconsin ginseng | #6 |
| medical acupuncture | #6 |
| intervention lymphedema | #6 |
| life toxicity | #6 |
| megestrol | #6 |
| selective poly | #6 |
| pharmaceutic aged aged | #6 |
| bf qol | #6 |
| hospitalized oncology patients | #6 |
| 71 sensitivity | #6 |
| participants sham acupuncture | #6 |
| active malignancy | #6 |
| imidazoles letrozole | #6 |
| severity neuropathic symptoms | #6 |
| inhaler bupropion | #6 |
| longacting methylphenidate | #6 |
| methylo | #6 |
| cancerrelated fatigue life | #6 |
| sadenosyllmethionine treatment | #6 |
| nci ctcae | #6 |
| nonanthracycline chemotherapy | #6 |
| placebo arm patients | #6 |
| versus combination | #6 |
| placebo hfs | #6 |
| breakthrough nausea | #6 |
| predictive illness surveys | #6 |
| therapy 10 weeks | #6 |
| data supporting | #6 |
| smoking abstinence rates | #6 |
| daily diary questionnaires | #6 |
| alliance clinical | #6 |
| apixaban cancer patients | #6 |
| neurological safety | #6 |
| flashes humans | #6 |
| loe guidelines | #6 |
| north central | #6 |
| mri trends | #6 |
| death kps | #6 |
| nicotine inhaler | #6 |
| studies vomiting | #6 |
| sensory scale | #6 |
| background chemotherapy | #6 |
| 500 mcg | #6 |
| 5fubased chemotherapy | #6 |
| staging patient outcomes | #6 |
| fatigue pilot study | #6 |
| her2directed therapy | #6 |
| hrqol breast neoplasms | #6 |
| olanzapine prevention | #6 |
| 4week intervention | #6 |
| proportion aes | #6 |
| depomedroxyprogesterone acetate | #6 |
| cipn treatment | #6 |
| placebo hot flashes | #6 |
| 5fu folfox | #6 |
| rs11572080 | #6 |
| highly emetogenic chemotherapy | #6 |
| induced sensory | #6 |
| venlafaxine therapy | #7 |
| outcomes primary outcomes | #7 |
| placebocontrolled trial | #7 |
| mpa arm | #7 |
| mucositis placebo | #7 |
| letrozole differences | #7 |
| study arms difference | #7 |
| cream versus | #7 |
| induced neuropathy | #7 |
| pain cipn | #7 |
| citalopram cyclohexanols | #7 |
| intermediate odx | #7 |
| weekly epoetin alfa | #7 |
| skindex16 | #7 |
| appetites | #7 |
| adjuvant interferon patients | #7 |
| uniscale qol | #7 |
| throat discomfort | #7 |
| chronic postmastectomy pain | #7 |
| bupropion relapse | #7 |
| induced rash | #7 |
| rs10509681 | #7 |
| sensitivity fecal | #7 |
| patient anthracycline | #7 |
| stage nodal status | #7 |
| uniscale | #7 |
| cancer patients anorexia | #7 |
| 5fu based chemotherapy | #7 |
| smoking 3 | #7 |
| week followup | #7 |
| model estimates survival | #7 |
| hemoccult hemoquant | #7 |
| neuropathy oxaliplatin | #7 |
| menopause hot | #7 |
| cryotherapy arm | #7 |
| vte recurrence doac | #7 |
| follow year | #7 |
| hemoquant | #7 |
| incidence rbc transfusion | #7 |
| study drug trial | #7 |
| accru | #7 |
| pregabalin prevention | #7 |
| cyclophosphamidedoxorubicin | #7 |
| fuinduced | #7 |
| symptom subscale | #7 |
| serum concentrations cytokines | #7 |
| venlafaxine day | #7 |
| cmt genes | #7 |
| transdermal clonidine | #7 |
| fluoxetine clinical trials | #7 |
| nausea cancer patients | #7 |
| weight concerns smokers | #7 |
| scheduled receive | #7 |
| paclitaxel peripheral | #7 |
| 1week baseline period | #7 |
| nutrition score | #7 |
| lymphedema education | #7 |
| intervention lymphedema status | #7 |
| illness antimetabolites | #7 |
| venlafaxine versus | #7 |
| minority smokers | #7 |
| 20 percent placebo | #7 |
| patients oral cryotherapy | #7 |
| patients hb response | #7 |
| toxic polyneuropathy | #7 |
| patients product | #7 |
| prevalence moderatetosevere | #7 |
| odx score | #7 |
| lower extremity symptoms | #7 |
| blind study | #7 |
| 12 treatment arms | #7 |
| cpmp | #8 |
| progestational | #8 |
| anecdotal | #8 |
| women hfs | #8 |
| 1355 | #8 |
| pros aes | #8 |
| direct oral factor | #8 |
| induced painful | #8 |
| 70305 | #8 |
| odx risk | #8 |
| evidence pharmacologic interventions | #8 |
| severe hot flashes | #8 |
| venlafaxine hot flashes | #8 |
| chronic neurotoxicity | #8 |
| mouth sores | #8 |
| series clinical trials | #8 |
| opioids moderate pain | #8 |
| fecal blood | #8 |
| paclitaxel pain | #8 |
| neuropathy pain | #8 |
| topic antineoplastic | #8 |
| oral placebo | #8 |
| administered systemically | #8 |
| epa survival | #8 |
| tamoxifeninduced hot flashes | #8 |
| cycle capecitabine | #8 |
| oxaliplatin neuropathy | #8 |
| placebo pilot study | #8 |
| stomatitis patients | #8 |
| symptoms neuropathy | #8 |
| paclitaxel severity | #8 |
| venous toxicity | #8 |
| factors cipn | #8 |
| prior chemotherapy exposure | #8 |
| treatment cinv | #8 |
| smokers weight concerns | #8 |
| antidepressant patients | #8 |
| life antibodies | #8 |
| greater toxicity | #8 |
| placebo suggestion | #8 |
| oxaliplatin paclitaxel | #8 |
| cancer survivors cipn | #8 |
| nonhormonal treatments | #8 |
| 18 months symptoms | #8 |
| recurrence colon cancer | #8 |
| oral iron placebo | #8 |
| raw data trials | #8 |
| efficacy newer antidepressants | #8 |
| sdt1 | #8 |
| neuropathy scale | #8 |
| agents newer | #8 |
| libido women | #8 |
| folfox dfs | #8 |
| flutamide placebo | #8 |
| neuropathic symptoms | #8 |
| oxaliplatin placebo | #9 |
| appetite weight | #9 |
| lymphedema hrqol | #9 |
| cipn patients | #9 |
| follow tests | #9 |
| 43 trials | #9 |
| apixaban lower rate | #9 |
| study treatment arm | #9 |
| antiemetic properties | #9 |
| topical antimetabolites | #9 |
| lmwh injections | #9 |
| disease receive | #9 |
| fatigue methylphenidate | #9 |
| skindex16 scores | #9 |
| patients provided | #9 |
| cancer patients cipn | #9 |
| prevention vomiting | #9 |
| relapse relapse prevention | #9 |
| incurable disease | #9 |
| vitality subscale | #9 |
| neuropathic symptoms patients | #9 |
| acid amines | #9 |
| cutaneous aged anesthetics | #9 |
| lamotrigine pain | #9 |
| letrozole day | #9 |
| genistein tumor growth | #9 |
| 5 nausea | #9 |
| surgical year | #9 |
| flash control | #9 |
| incidence colorectal adenomas | #9 |
| hot flashes tamoxifen | #9 |
| radiationinduced esophagitis | #9 |
| disease recurrence recurrence | #9 |
| baseline week week | #9 |
| questionnaires syndrome | #9 |
| mucositis pain | #9 |
| sensory axonopathy | #9 |
| medications evidence | #9 |
| dose dfmo | #9 |
| flashes hot | #9 |
| mometasone furoate placebo | #9 |
| fosaprepitant | #9 |
| lymphedema prevention | #9 |
| ambulatory analgesics | #9 |
| aged pilot | #9 |
| patients hot | #9 |
| trial paroxetine | #9 |
| numbness fingers | #9 |
| chemotherapy‐induced | #10 |
| advanced cancer life | #10 |
| ecog kps | #10 |
| life topic reproducibility | #10 |
| differences 5 years | #10 |
| megestrol acetate quality | #10 |
| cancerrelated fatigue fatigue | #10 |
| venlafaxine arm | #10 |
| nonhormonal therapies | #10 |
| flash data | #10 |
| oxaliplatin peripheral | #10 |
| shark cartilage | #10 |
| neoplasms neuralgia | #10 |
| qol anemia | #10 |
| scrambler therapy patients | #10 |
| cancerassociated anemia | #10 |
| inhibit cyp2d6 | #10 |
| patients treatment period | #10 |
| combination therapy relapse | #10 |
| incidence stomatitis | #10 |
| patients neurotoxic chemotherapy | #10 |
| antineoplastic agents humans | #10 |
| factes | #10 |
| physical consequences | #10 |
| asco guideline | #10 |
| symptomatic malignant ascites | #10 |
| pain medications patients | #10 |
| 40 arm | #10 |
| qol total | #10 |
| anorexia cachexia | #10 |
| minocycline reduction | #10 |
| aprepitant treatment | #10 |
| randomized placebo | #10 |
| cognitive chemotherapy | #10 |
| folfox 5fu | #10 |
| ctcae grades | #10 |
| adult cancers | #10 |
| trials demonstrated | #10 |
| phase iii | #10 |
| recommendations general population | #10 |
| frequency hot flashes | #10 |
| oxaliplatin trpa1 | #10 |
| gabapentin | #10 |
| nonhormonal treatment | #10 |
| vaginal dryness | #10 |
| data relatedness | #10 |
| humans megestrol | #10 |
| δ − | #10 |
| controlled randomized | #10 |
| life dietary supplements | #10 |
| sensitivity cancer | #10 |
| doses citalopram | #10 |
| antiemetic guidelines | #11 |
| fsfi female | #11 |
| efficacy black cohosh | #11 |
| electroanalgesia | #11 |
| olanzapine chemotherapy | #11 |
| flashes | #11 |
| anastrozole 10 | #11 |
| promising data | #11 |
| ativan | #11 |
| gbu | #11 |
| qol uniscale | #11 |
| combination treated | #11 |
| hydrazine sulfate | #11 |
| ginseng placebo | #11 |
| cancer undergoing | #11 |
| melt curve | #11 |
| dalteparin major bleeding | #11 |
| nicotine patch therapy | #11 |
| sensory neurotoxicity | #11 |
| erythropoietic response | #11 |
| prevalence neuropathic pain | #11 |
| vomiting cancer patients | #11 |
| translational component | #11 |
| institutional guideline | #11 |
| differences study arms | #11 |
| difficulty patients | #11 |
| reported incidences | #11 |
| physicians increased risk | #11 |
| diphenhydramine lidocaine | #11 |
| curve assay | #11 |
| cachexia clinical trials | #12 |
| venlafaxine women | #12 |
| toxicities groups | #12 |
| gait testing | #12 |
| hb response | #12 |
| recurrence comparisons | #12 |
| valerian placebo | #12 |
| adjuvant communication decision | #12 |
| patients cipn symptoms | #12 |
| cipn development | #12 |
| decreased libido | #12 |
| completed daily | #12 |
| leptin cck8 | #12 |
| individuals advanced adenomas | #12 |
| irox folfox | #12 |
| reported peripheral | #12 |
| cycles drugs | #12 |
| pluronic lecithin organogel | #12 |
| breast cancer letrozole | #12 |
| probability prospective studies | #12 |
| pilot trial levetiracetam | #12 |
| −307 | #12 |
| neurotoxic chemotherapy | #12 |
| capsaicin cream | #12 |
| hot flashes 95 | #12 |
| ctpm | #12 |
| oxaliplatin induced | #12 |
| rash quality | #12 |
| toxicity 4 weeks | #12 |
| apixaban dalteparin | #12 |
| venlafaxine hydrochloride | #12 |
| venlafaxine life | #13 |
| adenomas aspirin | #13 |
| nausea patients | #13 |
| initial 3 months | #13 |
| troublesome symptoms | #13 |
| patients diphenhydramine | #13 |
| education clinical practice | #13 |
| life neoplasm recurrence | #13 |
| flashes day | #13 |
| trial support | #13 |
| neuropathic pain surgery | #13 |
| adjuvant colon cancer | #13 |
| ncctg | #13 |
| autonomic scale | #13 |
| improve cancer | #13 |
| major bleeding doac | #13 |
| months smoking | #13 |
| anemia life | #13 |
| newer antidepressants placebo | #13 |
| hot flashes baseline | #13 |
| troubling | #13 |
| rs3213619 | #13 |
| andropause | #13 |
| 10 range | #13 |
| valerian sleep | #13 |
| patients breakthrough cinv | #13 |
| median hb | #13 |
| therapy benefits | #13 |
| neuropathy outcome | #13 |
| treatment advanced cancer | #13 |
| megestrol acetate therapy | #13 |
| bmd 1 year | #13 |
| common toxicity | #13 |
| oral anesthetics | #13 |
| estimates prognosis | #13 |
| patients advancedstage cancer | #13 |
| severity hot flashes | #13 |
| life investigation | #13 |
| 40 points 95 | #13 |
| paroxetine hot flashes | #13 |
| acute treatment vte | #13 |
| weight cachexia | #13 |
| venlafaxine paroxetine | #13 |
| adjuvant benefit | #13 |
| ais women | #13 |
| abh gel | #13 |
| incident exposure | #13 |
| 2000 update | #13 |
| provided data | #14 |
| genital symptoms | #14 |
| oxaliplatin vivo | #14 |
| diagnosis localized disease | #14 |
| based topical | #14 |
| prophylactic agent | #14 |
| fluoxymesterone | #14 |
| palliate | #14 |
| flash activity | #14 |
| 5fu surgery | #14 |
| stool dna | #14 |
| smokers placebo | #14 |
| recurrences patients | #14 |
| phase 3 months | #14 |
| biomarkers bone formation | #14 |
| marked toxicity | #14 |
| patients pain scores | #14 |
| oral iron | #14 |
| benefit toxicity | #14 |
| life anemia | #14 |
| adjuvant aromatase | #15 |
| advanced cancer methods | #15 |
| folfox irox | #15 |
| academic oncologists | #15 |
| triazoles zoledronic | #15 |
| acute diarrhea patients | #15 |
| vaginal dryness dyspareunia | #15 |
| syndromes peripheral | #15 |
| evidence treatment options | #15 |
| aes treatment | #15 |
| clinician perception | #15 |
| 16–28 | #15 |
| treatment weeks patients | #15 |
| mastectomy irradiation | #15 |
| week baseline | #15 |
| bfq | #15 |
| sternal skin conductance | #15 |
| oxaliplatininduced neurotoxicity | #15 |
| advanced malignant disease | #15 |
| acceptability device | #15 |
| trials gabapentin | #15 |
| suggestion guideline | #15 |
| grade age | #15 |
| highly emetogenic | #15 |
| agents life | #15 |
| taste alterations | #15 |
| lidocaine patch | #15 |
| life life survivors | #15 |
| therapy nicotine | #15 |
| androgen ablation therapy | #15 |
| persistent incisional pain | #15 |
| duloxetine cipn | #15 |
| monoclonal carcinoma antibodies | #15 |
| week darbepoetin | #15 |
| prognosis quality life | #15 |
| treatment cancer vte | #16 |
| female cancer survivors | #16 |
| tingling pain | #16 |
| patch therapy | #16 |
| loss appetite | #16 |
| symptoms numbness | #16 |
| patients venlafaxine | #16 |
| paclitaxel oxaliplatin | #16 |
| advancedstage cancer patients | #16 |
| breast gynecologic cancer | #16 |
| premenopausal women chemotherapy | #16 |
| endpoints baseline | #16 |
| induced hot | #16 |
| product time | #16 |
| dalteparin 95 | #16 |
| antiemetic agent | #16 |
| diarrhoea time | #16 |
| findings education | #16 |
| randomized trial aspirin | #16 |
| venlafaxine patients | #16 |
| stool dna test | #16 |
| mfsi | #16 |
| measurable evaluable disease | #16 |
| rash pruritus | #16 |
| vte apixaban | #16 |
| dfs folfox | #17 |
| screen detection | #17 |
| cancer menopause | #17 |
| institute common | #17 |
| recommendation suggestion | #17 |
| venlafaxine | #17 |
| flashes tamoxifen | #17 |
| fractional co2 | #17 |
| study tetracycline | #17 |
| 786 patients | #17 |
| leap study | #17 |
| 18 months women | #17 |
| inadequate control | #17 |
| device women | #17 |
| arthralgias | #17 |
| adenomas 1 | #17 |
| women metastatic | #17 |
| vaginal symptoms | #17 |
| reduction fatigue | #17 |
| oxaliplatin doses | #17 |
| leptin concentrations groups | #17 |
| breast cancer oestrogen | #17 |
| rs11849538 | #17 |
| oxaliplatin treated | #17 |
| crc patients patients | #17 |
| arhgef10 | #17 |
| receiving head | #18 |
| intervention guidelines | #18 |
| flash frequencies | #18 |
| 5 adjuvant | #18 |
| sternal skin | #18 |
| postmenopausal women letrozole | #18 |
| mri mastectomy | #18 |
| baseline 4 | #18 |
| randomized trials women | #18 |
| severity cipn | #18 |
| patients overview | #18 |
| data followup | #18 |
| severity hot | #18 |
| menopausal problems | #18 |
| 120000 | #18 |
| secondary endpoint analysis | #18 |
| placebo 04 | #18 |
| sigmoidoscopy tomography | #18 |
| prophylactic antiemetic therapy | #18 |
| oncology providers patients | #18 |
| patients informed decisions | #18 |
| oral dronabinol | #18 |
| standard prognostic | #18 |
| patients hb | #18 |
| patients irox | #18 |
| subsets age | #18 |
| treatment osteopenia | #18 |
| symptoms hormone | #18 |
| patients based chemotherapy | #19 |
| flash reduction | #19 |
| evidence status | #19 |
| bmd neoplasms chemotherapy | #19 |
| rs7349683 | #19 |
| 95 46 | #19 |
| previous colorectal | #19 |
| panax quinquefolius | #19 |
| folfox fluorouracil | #19 |
| neoplasms peripheral | #19 |
| 7 outcomes | #19 |
| treatment mastectomy | #19 |
| double blinded | #19 |
| oxaliplatin neurotoxicity | #19 |
| acute cancer | #19 |
| ncdf | #19 |
| physician reported | #19 |
| mastectomy methotrexate | #19 |
| life gabapentin | #19 |
| unpleasant taste | #19 |
| oxaliplatin carboplatin | #19 |
| minimal adverse effects | #19 |
| groups infliximab | #19 |
| n6 n5 | #19 |
| induced mucositis | #19 |
| fecal occult | #20 |
| cancer cancer therapy | #20 |
| placebo cream | #20 |
| appetite nutritional status | #20 |
| revisitation | #20 |
| study ginseng | #20 |
| pilot trials | #20 |
| advanced cancer study | #20 |
| emetogenic chemotherapy | #20 |
| life skindex16 | #20 |
| baseline week | #20 |
| receiving pelvic | #20 |
| therapeutic options treatment | #20 |
| reducing pain | #20 |
| diseases randomized | #20 |
| surveillance protocol | #20 |
| moderate pain patients | #20 |
| major bleeding treatment | #20 |
| progestational agents | #20 |
| numbness | #20 |
| palliating | #20 |
| fatigue 4 | #20 |
| placebo smokers | #20 |
| treatment options women | #21 |
| trial 12 months | #21 |
| cancer starting | #21 |
| receptorpositive breast cancer | #21 |
| studies methylphenidate | #21 |
| management cachexia | #21 |
| oral mucositis pain | #21 |
| refractory cachexia | #21 |
| chemotherapy agents | #21 |
| therapy adverse effects | #21 |
| cipn symptoms | #21 |
| crossover analysis | #21 |
| acetate patients | #21 |
| substantial problem | #21 |
| metastatic breast carcinoma | #21 |
| radiationinduced dermatitis | #21 |
| female menopause | #21 |
| routine test | #21 |
| gain patients | #22 |
| severity adverse events | #22 |
| emetogenic | #22 |
| patients 5 weeks | #22 |
| npy leptin | #22 |
| scores ≤ | #22 |
| patients testosterone | #22 |
| projects quality | #22 |
| location stage | #22 |
| n9741 | #22 |
| pharmacokinetics infliximab | #22 |
| 150 groups | #22 |
| asco panel | #22 |
| optumlabs | #22 |
| median time initiation | #22 |
| crossover phase | #22 |
| subcutaneous testosterone | #22 |
| doc time | #22 |
| guideline intervention | #22 |
| candidate single | #22 |
| sucralfate patients | #23 |
| followup tests | #23 |
| versus delayed | #23 |
| acetate middle | #23 |
| acupuncture hot | #23 |
| potential toxicities | #23 |
| detecting recurrence | #23 |
| aes qol | #23 |
| decision adjuvant | #23 |
| life ascites | #23 |
| mascc isoo | #23 |
| fsdsr | #23 |
| mcf7 cells genistein | #23 |
| stool dna testing | #23 |
| 5 pounds | #23 |
| tamoxifen octreotide | #24 |
| design rcts | #24 |
| apixaban treatment | #24 |
| female hot | #24 |
| prevention chemotherapy | #24 |
| abstract5fluorouracil | #24 |
| aged anorexia | #24 |
| mirtazapine patients | #24 |
| replacement testosterone | #24 |
| every3 | #24 |
| randomized 1 | #24 |
| weeks primary | #24 |
| ortho biotech | #24 |
| day chemotherapy | #24 |
| hrt survival | #24 |
| adjuvant decision making | #24 |
| n56 | #24 |
| topic design severity | #24 |
| aged amines | #24 |
| pilot clinical | #24 |
| doses schedules | #25 |
| mmf placebo | #25 |
| severe nausea vomiting | #25 |
| trial pilot | #25 |
| bpisf | #25 |
| vte trial | #25 |
| cancerassociated weight loss | #25 |
| criteria adverse | #25 |
| neoplasia screening | #25 |
| qol tools | #25 |
| recommendations basis | #25 |
| placebo arm treatment | #25 |
| lymphedema incidence | #25 |
| prevention nausea | #25 |
| women adjuvant tamoxifen | #25 |
| antiepileptic agent | #25 |
| cco guideline | #25 |
| nausea olanzapine | #25 |
| institutional guidelines | #25 |
| joints muscles | #26 |
| neoplasms estrogens | #26 |
| receiving oxaliplatin | #26 |
| agents prevention | #26 |
| clinical trials chemotherapy | #26 |
| undergoing adjuvant | #26 |
| regional breast | #26 |
| nci ctc | #26 |
| dose gabapentin | #26 |
| prior week | #26 |
| 2005 update | #26 |
| trial evaluate | #26 |
| combination weight loss | #26 |
| induced musculoskeletal | #26 |
| treatment arms | #26 |
| mfsisf | #26 |
| irradiation mastectomy | #26 |
| aiinduced | #26 |
| colorectal adenomas patients | #26 |
| syndrome menopause | #26 |
| oncology journals | #26 |
| cachexia carcinoma | #26 |
| hot flashes hf | #27 |
| prophylactic antiemetic | #27 |
| adjuvant 5fu | #27 |
| recommendations trials | #27 |
| events ctcae | #27 |
| lmwh survival | #27 |
| patients short term | #27 |
| fubased | #27 |
| smoking bupropion | #27 |
| nurse survey | #27 |
| series trials | #27 |
| valerian | #27 |
| lymphedema arm | #27 |
| antiemetic | #27 |
| neuropathy symptoms | #27 |
| alliance | #28 |
| chest rays | #28 |
| definitively | #28 |
| newer | #28 |
| treatment hot flushes | #28 |
| intractable palliative | #28 |
| primary endpoint proportion | #28 |
| matched general population | #28 |
| fluoxetine citalopram | #28 |
| standard prognostic factors | #28 |
| muscles joints | #28 |
| describers | #28 |
| lidocaine patches | #28 |
| gynecologic cancer survivors | #28 |
| mastectomy rate | #28 |
| prevent colorectal adenomas | #28 |
| paclitaxel cipn | #29 |
| asco guideline update | #29 |
| feet hands | #29 |
| mucositis study | #29 |
| statistical controversies | #29 |
| chemotherapy cipn | #29 |
| difluoromethylornithine dfmo | #29 |
| smokers bupropion | #29 |
| patients paclitaxel | #29 |
| points study | #29 |
| citalopram placebo | #29 |
| blood screening | #29 |
| survival arms | #29 |
| placebo arm | #29 |
| pain cancer survivors | #29 |
| efficacy venlafaxine | #29 |
| taxanebased chemotherapy | #29 |
| vitamin incidence | #29 |
| biological predictors | #29 |
| small pilot | #30 |
| alfa darbepoetin | #30 |
| loss postmenopausal | #30 |
| anthrapyrazoles | #30 |
| cipn pain | #30 |
| usual oncology | #30 |
| postmenopause predictive | #30 |
| contralateral axillary | #30 |
| benadryl | #30 |
| development cipn | #30 |
| diseases peripheral | #30 |
| management oral mucositis | #30 |
| pain oral | #30 |
| phase iii comparison | #30 |
| middle aged postmenopause | #30 |
| mild nausea | #30 |
| month duration | #30 |
| twoyear followup | #30 |
| term rectal | #31 |
| mastectomy mri | #31 |
| patients secondary analysis | #31 |
| sixtysix patients | #31 |
| symptomatic ascites | #31 |
| arms placebo | #31 |
| pain quality life | #31 |
| calcium magnesium | #31 |
| management menopausal symptoms | #31 |
| ixabepilone patients | #31 |
| middle aged perimenopause | #31 |
| prevention oral mucositis | #31 |
| treatment paclitaxel | #31 |
| patients races | #31 |
| treatment acute vte | #31 |
| efficacy methylphenidate | #31 |
| benefit dfs | #31 |
| vera gel | #32 |
| oncologist patients | #32 |
| women lymphedema | #32 |
| doubleblind trial | #32 |
| receiving highly | #32 |
| breast cancer symptoms | #32 |
| guideline endorsement | #32 |
| evidencebased guidance | #32 |
| female services | #32 |
| delayed chemotherapy | #32 |
| rash severity | #32 |
| camg | #32 |
| toxicity breast | #33 |
| isoo | #33 |
| neuropathy patients | #33 |
| patients taxol | #33 |
| acupuncture hot flashes | #33 |
| week treatment | #33 |
| sensitivity polyps | #33 |
| neoplasms carboplatin | #33 |
| 4week followup | #33 |
| pursuant | #33 |
| questionnaires total | #33 |
| blind manner | #33 |
| smokers randomized | #33 |
| dose megestrol | #33 |
| patients cinv | #33 |
| hands feet | #33 |
| chemotherapeutic regimens | #33 |
| aloe vera gel | #33 |
| painful cipn | #33 |
| therapy bupropion | #33 |
| survival advanced cancer | #33 |
| fingers hands | #33 |
| breast neoplasms life | #33 |
| increased difficulty | #33 |
| instruments life | #33 |
| chemotherapy hec | #34 |
| patients acitretin | #34 |
| continuation study | #34 |
| toxicity fluorouracil | #34 |
| patients nausea | #34 |
| inhibitors venlafaxine | #35 |
| 4 week | #35 |
| united states hrqol | #35 |
| dawley statistics | #35 |
| patients tools | #35 |
| carcinoembryonic antigen levels | #35 |
| cancer international society | #35 |
| stomatitis | #35 |
| levels week | #35 |
| cipn severity | #35 |
| formal consensus process | #35 |
| prevention chemotherapyinduced nausea | #35 |
| moderatetosevere patients | #35 |
| major bleeding lmwh | #35 |
| trial designed | #35 |
| primary outcomes trials | #35 |
| treating cancer | #35 |
| mometasone placebo | #36 |
| pyrexia patients | #36 |
| myalgias | #36 |
| nk1ras | #36 |
| secondary prevention measures | #36 |
| pain pilot | #36 |
| stages colorectal cancer | #36 |
| doxepin | #36 |
| head neck radiotherapy | #36 |
| lymphedema treatment | #36 |
| cohosh | #36 |
| tnfα study | #36 |
| mc5 | #37 |
| chronic nausea | #37 |
| cancerrelated fatigue | #37 |
| alleviation | #37 |
| topic humans life | #37 |
| survival supportive | #37 |
| nausea neoplasms | #37 |
| p00052 | #37 |
| study intravenous | #37 |
| symptoms cancer | #37 |
| topic stomatitis | #37 |
| ctcae | #37 |
| early integrated | #37 |
| planned sample size | #37 |
| global impression | #37 |
| oncology providers | #38 |
| patients highdose melphalan | #38 |
| 5ht3ras | #38 |
| trial conducted | #38 |
| fluorouracil based | #38 |
| women metastatic disease | #38 |
| illness purpose | #38 |
| patients taxanes | #38 |
| sensitization nociceptors | #38 |
| individual item | #38 |
| tests controlled trials | #38 |
| relationships populations | #38 |
| european organisation cancer | #39 |
| acids drug | #39 |
| 3 agents | #39 |
| crushed ice | #39 |
| cohort type | #39 |
| trials oncology | #39 |
| arm placebo | #39 |
| treatment breakthrough | #39 |
| arm difference | #39 |
| blind crossover | #39 |
| chi2 tests | #39 |
| qol clinical trials | #39 |
| grade 2 toxicity | #39 |
| study double | #39 |
| menopause gsm | #39 |
| appetite patients | #40 |
| prevent colorectal | #40 |
| initial mastectomy | #40 |
| treatment analyses | #40 |
| cachexia clinical | #40 |
| terminology criteria | #40 |
| single dose placebo | #40 |
| patients lamotrigine | #40 |
| mastectomy chemotherapy | #40 |
| method fatigue | #40 |
| difluoromethylornithine | #40 |
| arthralgia breast | #40 |
| topic reproducibility surveys | #40 |
| smokers weight | #41 |
| bupropion smokers | #41 |
| symptoms 12 months | #41 |
| cure recurrence | #41 |
| united states guidelines | #41 |
| relapse 3 months | #41 |
| zoledronic acid bmd | #41 |
| trial performed | #41 |
| drug evaluation studies | #41 |
| treatment period | #41 |
| undergoing androgen | #41 |
| gabapentin placebo | #41 |
| placebo venlafaxine | #42 |
| patients completed | #42 |
| appetite body | #42 |
| oral gabapentin | #42 |
| chemotherapy day | #42 |
| neuronal protection | #42 |
| treating institution | #42 |
| nortriptyline placebo | #42 |
| transdermal gel | #42 |
| patients incurable | #42 |
| location age | #42 |
| randomized doubleblind trial | #42 |
| desipramine patients | #43 |
| median weight | #43 |
| highdose interferon | #43 |
| postsurgical | #43 |
| preliminary insights | #43 |
| sex location | #43 |
| baseline fatigue | #43 |
| 5 induced | #43 |
| dietary supplements life | #43 |
| nonpain | #44 |
| bupropion placebo | #44 |
| risk cipn | #44 |
| trial benefit | #44 |
| pain reduction patients | #44 |
| disagreement | #44 |
| weeks efficacy | #44 |
| outcome gamma | #44 |
| surveillance united states | #44 |
| vaginal moisturizer | #44 |
| sensory symptoms | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| collaborative effort | #44 |
| fisher tests | #45 |
| 5 years incidence | #45 |
| objective tumor regression | #45 |
| piroxantrone | #45 |
| humans peripheral | #45 |
| conclusion trial | #45 |
| menogaril | #45 |
| ginseng panax quinquefolius | #45 |
| rash grade | #45 |
| historic controls | #45 |
| acute pain patients | #45 |
| genitourinary syndrome menopause | #45 |
| survivors colorectal cancer | #45 |
| study gaba | #46 |
| vaccines melanoma | #46 |
| factor prognostic | #46 |
| longitudinal methods | #46 |
| clinical problem | #46 |
| middle aged patient | #46 |
| adverse symptoms | #46 |
| acute skin toxicity | #46 |
| megestrol acetate treatment | #46 |
| radiationinduced oral mucositis | #46 |
| putative mechanism | #46 |
| patients advanced adenomas | #46 |
| epoetin alfa placebo | #46 |
| item measures | #46 |
| iii colon cancer | #46 |
| cisplatin neuropathy | #46 |
| randomized comparison | #46 |
| nonpharmacological therapy | #46 |
| chemotherapy antineoplastic | #46 |
| radiotherapy randomized | #46 |
| current manuscript | #46 |
| phase iii life | #46 |
| aged mometasone | #47 |
| genetic predictors | #47 |
| average pain | #47 |
| cachexia female | #47 |
| screening setting | #47 |
| differences pros | #47 |
| neoplasms parenteral nutrition | #47 |
| mascc | #47 |
| bipn | #47 |
| dose paclitaxel | #47 |
| darbepoetin alfa patients | #47 |
| twopart | #47 |
| nausea day | #48 |
| stratification factor | #48 |
| neck radiotherapy | #48 |
| genitourinary symptoms | #48 |
| placebo gabapentin | #48 |
| qol female humans | #48 |
| physical examinations | #48 |
| menopause life | #48 |
| oxybutynin | #48 |
| patientclinician communication | #49 |
| chemotherapy nausea | #49 |
| sham arm | #49 |
| flie | #49 |
| female cancer | #49 |
| receiving androgen | #50 |
| pain numbness | #50 |
| antiserotonergic | #50 |
| replens | #50 |
| placebos randomized | #50 |
| hot flashes hfs | #50 |
| models stage | #50 |
| cachexia | #50 |
| cancer survivors fatigue | #50 |
| time conclusions | #50 |
| mastectomy pain | #50 |
| regional hypothermia | #51 |
| patients 8 weeks | #51 |
| patients cancer pain | #51 |
| transdermal testosterone | #51 |
| vomiting chemotherapy | #51 |
| effective treating | #51 |
| blinded placebo | #51 |
| genitourinary syndrome | #51 |
| cisplatin humans | #51 |
| treatment adt | #52 |
| black cohosh | #52 |
| differences treatment arms | #52 |
| management chemotherapy | #52 |
| metaanalysis incidence | #52 |
| risk bone loss | #52 |
| 80k | #52 |
| trastuzumab orr | #52 |
| aged orchiectomy | #52 |
| control nausea | #53 |
| receiving radiotherapy | #53 |
| toxicity time | #53 |
| cancer venous | #53 |
| nervous peripheral | #53 |
| tamoxifen antineoplastic agents | #53 |
| potential adjuvant | #53 |
| purposepatients | #53 |
| 20 data | #54 |
| blood testing | #54 |
| standard placebo | #54 |
| recurrent disease | #54 |
| pilot trial | #54 |
| treatment months | #54 |
| levetiracetam treatment | #54 |
| double‐blind trial | #54 |
| severe hot | #54 |
| antiemetics antineoplastic | #54 |
| life topic humans | #54 |
| scalp cooling | #55 |
| bupropion treatment | #55 |
| acupuncture cancer | #55 |
| fatigue inventory | #55 |
| cachexia therapy | #55 |
| treatment tobacco dependence | #55 |
| symptoms therapy | #55 |
| cancerdirected therapy | #55 |
| serial levels | #55 |
| symptoms hot | #56 |
| undergoing chemotherapy | #56 |
| xaliproden | #56 |
| adjuvant endocrine treatment | #56 |
| diseases antineoplastic | #56 |
| time placebo | #56 |
| carboplatin female humans | #56 |
| benefit scale | #57 |
| adjuvant colon | #57 |
| common terminology | #57 |
| recurrence symptoms | #57 |
| placebo solution | #57 |
| 12 courses | #57 |
| undergoing treatment | #58 |
| completion adjuvant chemotherapy | #58 |
| points placebo | #58 |
| major bleeding enoxaparin | #58 |
| skin dermatitis | #58 |
| topical gel | #58 |
| compared oral | #58 |
| cachexia weight loss | #58 |
| ferric gluconate | #58 |
| quality life questionnaire | #58 |
| pain peripheral | #58 |
| limited degree | #58 |
| patients hec | #59 |
| ocular irritation | #59 |
| chemotherapyinduced nausea | #59 |
| placebo citalopram | #59 |
| safety rivaroxaban | #59 |
| data understanding | #59 |
| chemotherapy cognitive | #59 |
| weight appetite | #59 |
| osteopaenia | #59 |
| coprescription | #59 |
| study medication | #60 |
| serotonergic effects | #60 |
| patients mirtazapine | #60 |
| anticonvulsants antidepressive | #60 |
| hb baseline | #60 |
| colonoscopically | #60 |
| tamoxifen metabolism | #61 |
| pipn | #61 |
| cancer patients study | #61 |
| standard dosing | #61 |
| emla cream | #61 |
| doubleblind | #61 |
| lymphedema women | #61 |
| 1 week treatment | #61 |
| topic surveys life | #61 |
| paroxetine fluoxetine | #61 |
| caregivers pain | #61 |
| bleomycin patients | #61 |
| sensitivity individuals | #61 |
| 3 randomized | #61 |
| venlafaxine placebo | #62 |
| recurrent disease patients | #62 |
| induced taste | #62 |
| pain bleeding | #62 |
| fluorouracil induced | #62 |
| chemotherapy dose | #62 |
| efficacy fluoxetine | #62 |
| ocular toxicity | #62 |
| dermatological toxicities | #62 |
| alpha weight | #62 |
| 105 months | #63 |
| patients disease recurrence | #63 |
| antibodies monoclonal carcinoma | #63 |
| lessen | #63 |
| ncictc | #63 |
| prior chemotherapy regimen | #63 |
| aged placebos | #63 |
| integrative oncology | #63 |
| anorexia patients | #63 |
| aged nausea | #64 |
| treatment chemotherapy | #64 |
| allelic variability | #64 |
| improvement sexual function | #64 |
| cyproheptadine | #64 |
| rivaroxaban enoxaparin | #64 |
| bupropion nicotine | #64 |
| carboplatin oxaliplatin | #64 |
| cyclohexanols | #64 |
| alleviate | #64 |
| incidence rash | #64 |
| patients cancer types | #64 |
| painful peripheral neuropathy | #64 |
| versus placebo | #64 |
| validated patient | #65 |
| patients comparisons | #65 |
| dalteparin treatment | #65 |
| 75 daily | #65 |
| administration paclitaxel | #65 |
| patients minocycline | #65 |
| appetite weight loss | #65 |
| agents double | #65 |
| survivorship issues | #65 |
| 4 weeks week | #65 |
| efficacy toxicity | #65 |
| acetate therapy | #66 |
| placebo months | #66 |
| diseases neoplasms | #66 |
| food intake patients | #66 |
| study gabapentin | #66 |
| nicotine nasal | #66 |
| oncology clinical | #66 |
| clinician training | #67 |
| estrogen suppression | #67 |
| life topic | #67 |
| qol fatigue | #67 |
| target doses | #67 |
| 46 95 | #68 |
| cachexia weight | #68 |
| baseline study | #68 |
| subcutaneous dalteparin | #68 |
| induced dermatitis | #68 |
| patients randomized | #68 |
| hormonal therapies | #68 |
| hec | #68 |
| prevention smoking | #68 |
| pilocarpine treatment | #68 |
| vasomotor symptoms women | #69 |
| gained weight | #69 |
| skin surveys | #69 |
| ongoing loss | #69 |
| debilitating | #69 |
| fsfi score | #69 |
| development severity | #70 |
| item score | #70 |
| women ais | #70 |
| induced ovarian | #70 |
| surgery cancer | #70 |
| multifactorial syndrome | #70 |
| nonsignificant trends | #70 |
| chemotherapy anemia | #70 |
| anthrapyrazole | #71 |
| weight compared | #71 |
| infliximab combination | #71 |
| week percentage | #71 |
| life referral | #71 |
| incidence severity | #71 |
| major bleeding apixaban | #71 |
| humans lignans | #72 |
| effects ginseng | #72 |
| systemic retinoids | #72 |
| trials planning | #72 |
| oral drug administration | #72 |
| placebo patches | #72 |
| cisplatin treated | #72 |
| patients pilot | #72 |
| weeks placebo | #73 |
| stage primary | #73 |
| chemotherapy supportive | #73 |
| ergotamines | #73 |
| chemoprevention trial | #73 |
| prospective pilot trial | #73 |
| ginseng treatment | #73 |
| placebo | #73 |
| fractional co2 laser | #74 |
| dronabinol | #74 |
| anemia antineoplastic | #74 |
| rcts systematic reviews | #74 |
| women estrogen therapy | #74 |
| qli | #74 |
| rash | #74 |
| receiving chemotherapy | #74 |
| trial evaluating | #74 |
| nervous diseases | #75 |
| prevention | #75 |
| 353 patients | #75 |
| acid supplement | #75 |
| cancerrelated fatigue crf | #75 |
| acute skin | #76 |
| blind clinical | #76 |
| weekly arm | #76 |
| inhibitors tamoxifen | #76 |
| cycles cycle | #76 |
| dose 90 | #77 |
| 95 01 | #77 |
| tamoxifen postmenopausal | #77 |
| alliance patients | #77 |
| anemia darbepoetin | #77 |
| hospice staff | #77 |
| anorexia weight loss | #77 |
| week p005 | #77 |
| cancer randomized | #77 |
| breast cancer paclitaxel | #77 |
| values data | #78 |
| tamoxifen postmenopausal women | #78 |
| female humans insurance | #78 |
| 3 arm | #78 |
| patients zoledronic acid | #78 |
| vte recurrence | #79 |
| pain syndrome | #79 |
| surgery year | #79 |
| symptoms sensitivity | #79 |
| serum concentrations infliximab | #79 |
| therapy antineoplastic | #79 |
| week schedule | #79 |
| efficacy lamotrigine | #79 |
| patients darbepoetin alfa | #79 |
| vomiting antiemetics | #80 |
| zoledronic acid treatment | #80 |
| foot syndrome | #80 |
| isoflavone supplements | #80 |
| time mastectomy | #80 |
| week 4 | #80 |
| life phase iii | #80 |
| period crossover | #81 |
| oral oncology | #81 |
| patients treatment arms | #81 |
| study march | #81 |
| lowmolecular weight heparin | #81 |
| patient qol | #81 |
| guideline recommendation | #81 |
| greater weight gain | #82 |
| paroxetine patients | #82 |
| standard clinical | #82 |
| suggestion | #82 |
| backgroundchemotherapy | #82 |
| bupropion smoking | #82 |
| patients participating | #83 |
| trpv1 trpa1 | #83 |
| orbital stability | #83 |
| day weeks | #83 |
| recommendations article | #83 |
| cinv patients | #84 |
| trpm8 trpa1 | #84 |
| method female | #84 |
| zinc sulfate | #84 |
| ice pack | #85 |
| systematic reviews rcts | #85 |
| neoplasm metastasis neoplasms | #85 |
| cancer weight | #85 |
| treatment nicotine dependence | #86 |
| cryotherapy patients | #86 |
| ttf survival | #86 |
| mayo clinic | #86 |
| receiving placebo | #86 |
| therapyinduced | #87 |
| primary symptom | #87 |
| incidence osteoporosis | #87 |
| life cachexia | #87 |
| serum hepcidin levels | #87 |
| frequency severity | #87 |
| baseline arms | #87 |
| week 5 | #87 |
| methodspatients | #87 |
| nicotine nasal spray | #87 |
| pilot study safety | #87 |
| acp documentation | #88 |
| anecdotal reports | #88 |
| integrative therapies | #88 |
| putative mediator | #89 |
| iu daily | #89 |
| treatment fatigue | #89 |
| cancer vte | #89 |
| outcome venlafaxine | #90 |
| clinical oncology asco | #90 |
| male chemotherapy | #90 |
| morphine pharmacokinetics | #90 |
| endoxifen concentrations | #91 |
| iii efficacy | #91 |
| symptoms including | #91 |
| arm treatment | #91 |
| scores placebo | #91 |
| ncorp | #91 |
| delayed cinv | #91 |
| tolerated patients | #91 |
| patients upfront | #92 |
| cisplatin oxaliplatin | #92 |
| completion chemotherapy | #92 |
| nerve pain | #92 |
| patients paroxetine | #92 |
| trials treatment | #92 |
| ameliorating | #93 |
| duloxetine hydrochloride | #94 |
| quiet stance | #94 |
| apixaban dose | #94 |
| questionnaires survival | #94 |
| mometasone | #94 |
| breast cancer survivors | #94 |
| arm 3 | #94 |
| anemic patients | #94 |
| neoplasms quality life | #94 |
| 1 primary | #94 |
| cancerrelated pain | #95 |
| patients appetite | #95 |
| common symptoms | #95 |
| alfa patients | #95 |
| 0 10 | #96 |
| prevention management | #96 |
| mayo clinic rochester | #96 |
| patients completion | #96 |
| udi | #96 |
| ccop | #96 |
| failure chemotherapy | #96 |
| hlaa2 patients | #96 |
| adjuvant therapy survival | #97 |
| pyrexia | #97 |
| acute vte | #97 |
| paclitaxel patient | #97 |
| oral mucositis patients | #97 |
| identical placebo | #98 |
| 15 points | #98 |
| preliminary data | #98 |
| crnmb | #98 |
| completed study | #98 |
| alleviating | #98 |
| painful area | #98 |
| agents paclitaxel | #98 |
| text review | #98 |
| treatment tolerability | #98 |
| induced esophagitis | #99 |
| 5fu leucovorin | #99 |
| 4 weeks baseline | #99 |
| 5fluorouracil oxaliplatin | #99 |
| pregnadienediols | #99 |
| topic cyclophosphamide | #99 |
| patient questionnaires | #99 |
| bcca | #99 |
| patient medical | #99 |
| fatigue insomnia | #99 |
| difference incidence | #99 |
| 10 doses | #100 |
| male sex factors | #100 |
| qlq | #100 |
| clinician communication | #100 |
| oncology outpatients | #100 |
| survival nsclc | #100 |
| lidocaine lidocaine | #101 |
| antineoplastic agents life | #101 |
| oncology clinicians | #101 |
| 5 based | #101 |
| postresection | #101 |
| 275 patients | #101 |
| nortriptyline | #101 |
| humans life | #101 |
| oncology asco | #101 |
| lung cancer chemoprevention | #101 |
| methods trial | #102 |
| placebo 1 year | #102 |
| reported effects | #103 |
| variance clinical trials | #103 |
| quality life data | #104 |
| purposeprevious | #104 |
| patients anorexia | #104 |
| races ethnicities | #104 |
| 3106 | #104 |
| chemotherapy cycle | #105 |
| phytogenic clinical trials | #105 |
| leap | #105 |
| diseases treatment | #105 |
| patients 150 | #105 |
| 12 24 months | #105 |
| dalteparin patients | #106 |
| nutritional determinants | #106 |
| dfmo | #106 |
| neuropathy | #106 |
| stool samples patients | #106 |
| infusion site | #106 |
| compounds oxaliplatin | #106 |
| trial studies | #106 |
| months relapse | #106 |
| pain intensity ratings | #107 |
| humans menopause | #107 |
| anastrozole letrozole | #107 |
| cycle cycles | #107 |
| urogenital diseases | #107 |
| versus dexamethasone | #107 |
| valeriana officinalis | #107 |
| epoetin alfa patients | #107 |
| life topic severity | #108 |
| relapse prevention | #108 |
| breast cancer tamoxifen | #108 |
| women experience | #108 |
| time toxicity | #108 |
| week study | #108 |
| strong prognostic factor | #109 |
| mouthwash | #109 |
| treatment cancer pain | #109 |
| female urogenital | #109 |
| levocarnitine | #109 |
| women vasomotor symptoms | #109 |
| patients guideline | #109 |
| patients cancer treatment | #110 |
| combined paclitaxel | #110 |
| clinic rochester | #110 |
| oxaliplatin therapy | #110 |
| life adverse events | #110 |
| egfr inhibitor | #111 |
| vomiting adult | #111 |
| prevention bone loss | #111 |
| cmf chemotherapy | #111 |
| function suppression | #112 |
| insomnia pain | #112 |
| dosing schedules | #112 |
| visits patient | #113 |
| vaginal diseases | #113 |
| treatment arms patients | #113 |
| reassess | #113 |
| adverse events ctcae | #113 |
| agents hormonal | #113 |
| colorectal neoplasia | #113 |
| –iii | #113 |
| functional iron deficiency | #113 |
| patients arms | #113 |
| vestibulitis | #113 |
| cachexia humans | #114 |
| acitretin | #114 |
| months 3 | #114 |
| therapy induced | #114 |
| hfsd | #114 |
| single nucleotide variants | #114 |
| patients olanzapine | #114 |
| qol patient | #114 |
| dietary lignans | #114 |
| diseases breast | #114 |
| alopecia patients | #114 |
| crci | #115 |
| rivaroxaban venous | #115 |
| letrozole tamoxifen | #115 |
| combination nicotine | #115 |
| laser therapy lasers | #115 |
| studies randomized | #115 |
| patients anthracycline | #115 |
| treatment arm | #116 |
| placebo postmenopausal women | #116 |
| symptoms chemotherapy | #117 |
| 2007 guidelines | #117 |
| oral factor | #117 |
| patients peripheral neuropathy | #117 |
| induction ornithine decarboxylase | #117 |
| nk1 receptor antagonist | #117 |
| recurrence diagnosis | #118 |
| appetite stimulant | #118 |
| oral antineoplastic agents | #118 |
| preventive therapies | #119 |
| trpa1 trpv1 | #119 |
| noradrenaline reuptake | #119 |
| patients weekly paclitaxel | #119 |
| 3915 | #119 |
| diseases pain | #119 |
| trials conducted | #119 |
| definition classification | #120 |
| participants arms | #120 |
| treatment weeks | #120 |
| 750 day | #120 |
| resultswhile | #120 |
| original report | #120 |
| olanzapine placebo | #120 |
| clinical histories | #120 |
| postmenopausal postmenopause | #121 |
| placebo double | #121 |
| fullerton | #121 |
| induced ocular | #121 |
| patients cancers | #121 |
| untoward | #121 |
| hormonal agents | #121 |
| oxaliplatin folfox | #122 |
| nervous agents | #122 |
| cancer multiple | #122 |
| skin pain | #123 |
| objective review | #123 |
| rolapitant | #123 |
| acute oral | #123 |
| weeks 4 | #123 |
| netupitant | #123 |
| stable dose | #123 |
| cancer quality | #123 |
| surgery analysis | #123 |
| treatment letrozole | #124 |
| patients diploid tumors | #124 |
| neuropathic pain patients | #124 |
| isoflavones genistein | #124 |
| survivors breast cancer | #124 |
| pros baseline | #124 |
| rivaroxaban compared | #124 |
| week dose | #125 |
| 90 dose | #125 |
| 1 month patients | #125 |
| factors odds | #126 |
| resultsfour | #126 |
| neurotoxic agents | #126 |
| patients physicians | #127 |
| fsfi | #127 |
| anorexia | #127 |
| promising agents | #127 |
| hormonal breast | #127 |
| genetic quality | #127 |
| diagnosis metastatic disease | #127 |
| recurrent adenomas | #127 |
| uncommon variants | #128 |
| weight concerns | #128 |
| cancerassociated vte | #128 |
| belladonna | #128 |
| arms patients | #128 |
| alfa erythropoietin | #128 |
| postural instability | #129 |
| 5 leucovorin | #129 |
| resultsforty | #129 |
| agents neoplasms | #129 |
| clinical trial patients | #129 |
| vomiting cinv | #129 |
| neoplasms quality | #129 |
| problem patients | #130 |
| patientreported outcome | #130 |
| serum baseline | #130 |
| control arms | #130 |
| cancer fatigue | #131 |
| bmd tscore | #131 |
| treatment toxicities | #131 |
| prognostic variables | #131 |
| function fsfi | #131 |
| 150 iu | #131 |
| neurotoxicity syndromes | #132 |
| relapse smoking | #132 |
| onycholysis | #132 |
| cancerrelated symptoms | #132 |
| pilot data | #132 |
| efficacy vitamin | #132 |
| assessable | #133 |
| cachexia patients | #133 |
| progress report | #133 |
| topical treatment | #133 |
| ganglion block | #134 |
| symptom control | #134 |
| ginseng panax | #134 |
| endodermal sinus tumor | #134 |
| 5 placebo | #134 |
| bmd postmenopausal women | #135 |
| 150 women | #135 |
| cancers patients | #135 |
| toxt | #135 |
| cold hyperalgesia | #135 |
| chemotherapy 5 | #135 |
| common adverse effects | #135 |
| agents generation | #135 |
| bothersome | #136 |
| weekly therapy | #136 |
| patientlevel pooled analysis | #136 |
| symptomatic benefit | #136 |
| painful neuropathy | #136 |
| npy levels | #136 |
| study trials | #137 |
| poor qol | #137 |
| intrapatient | #137 |
| percentage reduction | #137 |
| life physical function | #137 |
| severe fatigue | #137 |
| stage cancer | #137 |
| substantial benefit | #137 |
| agents bortezomib | #137 |
| grade stage | #138 |
| hfs patients | #138 |
| accrued | #138 |
| zoledronic | #138 |
| incurable cancer | #139 |
| factbr | #139 |
| chemoprevention studies | #139 |
| therapy breast | #139 |
| underwent mastectomy | #139 |
| advanced lung | #139 |
| liquid suspension | #140 |
| breast chest wall | #140 |
| patients advanced cancer | #140 |
| paclitaxel weekly | #141 |
| patients placebo | #141 |
| oxaliplatin chemotherapy | #141 |
| patients levetiracetam | #142 |
| financial concerns | #142 |
| tamoxifen placebo | #142 |
| disclose | #142 |
| medicine clinical | #143 |
| protocols breast | #143 |
| fluorouracil 5 | #143 |
| allopurinol placebo | #144 |
| preoperative magnetic | #144 |
| snv | #144 |
| european organisation | #144 |
| vaginal cytology | #145 |
| evidence loe | #145 |
| agents bone | #145 |
| debilitating condition | #145 |
| eortc qlq | #145 |
| fluorouracil humans | #145 |
| eligible women | #146 |
| surgery type | #146 |
| backgroundwomen | #148 |
| oral olanzapine | #148 |
| dietary counselling | #148 |
| volatile plants | #148 |
| numeracy | #149 |
| desipramine treatment | #149 |
| n201 | #150 |
| adjuvant systemic | #150 |
| predict recurrence | #150 |
| venlafaxine treatment | #150 |
| methodologic | #151 |
| patients receive | #151 |
| women estrogen | #151 |
| prior chemotherapy regimens | #151 |
| intravenous access | #151 |
| response rate survival | #151 |
| daily diaries | #151 |
| multinational association | #151 |
| 14 week | #152 |
| ovarian function suppression | #152 |
| tumor recurrence patients | #152 |
| groups symptoms | #152 |
| caa patients | #152 |
| oral mucositis | #152 |
| balance impairments | #152 |
| cramping | #153 |
| 80 dose | #154 |
| carboplatin trastuzumab | #154 |
| dermatomes | #155 |
| adjuvant systemic therapy | #155 |
| cindices | #155 |
| life randomized | #156 |
| mangafodipir | #156 |
| methods randomized | #156 |
| fsds | #156 |
| integrated palliative | #156 |
| combination chemotherapy cisplatin | #156 |
| vinblastine bleomycin | #156 |
| hyperalimentation | #156 |
| infliximab 5 | #156 |
| common terminology criteria | #157 |
| breast cancer trastuzumab | #157 |
| racially diverse | #157 |
| women breast carcinoma | #157 |
| gait stability | #157 |
| oncology study | #158 |
| study initiation | #158 |
| arm versus | #158 |
| vomiting nausea | #158 |
| weekly doses | #159 |
| iii clinical | #159 |
| chemotherapy breast cancer | #159 |
| induced nausea | #159 |
| survivors colorectal | #159 |
| physicians patients | #159 |
| stellate ganglion | #160 |
| european organisation treatment | #160 |
| cancer pain patients | #160 |
| treatment postmenopausal women | #160 |
| chemotherapy quality | #160 |
| paclitaxel taxol | #160 |
| major problem | #160 |
| women hormone therapy | #161 |
| estrogen depletion | #161 |
| risk infertility | #161 |
| validity life | #161 |
| data efficacy | #163 |
| efficacy women | #164 |
| neoplasms pain | #164 |
| cisplatin vinblastine | #165 |
| mometasone furoate | #165 |
| current project | #165 |
| pharmacokinetic analyses | #166 |
| patients 1 month | #166 |
| skeletal events | #166 |
| illness surveys questionnaires | #167 |
| osteoporosis prevention | #167 |
| life topic surveys | #167 |
| chemotherapy groups | #168 |
| chemotherapy‐induced nausea | #168 |
| anthracycline | #168 |
| direct inhibitors | #168 |
| 432 patients | #169 |
| patients adenomas | #169 |
| patients data | #169 |
| dosing patients | #169 |
| menopause symptoms | #169 |
| ixabepilone | #170 |
| management chronic pain | #170 |
| global quality | #171 |
| disease cmt | #171 |
| daily placebo | #171 |
| prospective clinical trials | #171 |
| rochester | #171 |
| chemotherapy completion | #172 |
| prestudy | #172 |
| placebos | #173 |
| lamotrigine placebo | #173 |
| hot flushes | #173 |
| impaired balance | #173 |
| judicious | #173 |
| label pilot | #173 |
| 1 year therapy | #173 |
| methylphenidate placebo | #174 |
| pilot feasibility study | #174 |
| prospective evaluation | #174 |
| phase iii trial | #174 |
| diarrhoea patients | #174 |
| arthralgia | #175 |
| male breast cancer | #175 |
| cancer cancer treatment | #175 |
| decreased quality | #175 |
| physician order | #175 |
| baseline weight | #176 |
| weeks women | #177 |
| treatment 14 | #177 |
| life assessments | #177 |
| thirty percent | #178 |
| bodyweights | #178 |
| bolus fluorouracil | #179 |
| bothered | #179 |
| life baseline | #179 |
| expected benefits | #179 |
| treatmentrelated toxicity | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| escalations | #182 |
| gain weight | #182 |
| ginseng | #182 |
| darbepoetin | #182 |
| oxaliplatin 5fluorouracil | #182 |
| peri postmenopausal women | #183 |
| organisation treatment | #183 |
| toxicity criteria | #183 |
| prognostic criteria | #184 |
| tube primary | #184 |
| received oral | #184 |
| infliximab antibodies | #184 |
| acetyll | #184 |
| white smokers | #184 |
| biostatisticians | #184 |
| effects chemotherapy | #184 |
| acute pain | #184 |
| reported sexual | #185 |
| outcome measures life | #185 |
| additional chemotherapy | #185 |
| arm volume | #186 |
| cinv | #187 |
| patients drug | #187 |
| treatment 4 weeks | #187 |
| delayed nausea | #187 |
| treating | #187 |
| week follow | #188 |
| strong prognostic | #188 |
| troublesome | #188 |
| lessened | #188 |
| reduction therapy | #188 |
| management breast cancer | #188 |
| tamoxifen letrozole | #188 |
| adjuvant decision | #188 |
| aching | #189 |
| neoplasia female humans | #189 |
| oxaliplatin dose | #189 |
| antiemetic regimens | #190 |
| aged nitriles | #190 |
| week 1 | #190 |
| survivors breast | #190 |
| protocol therapy | #190 |
| placebo study | #190 |
| completed baseline | #191 |
| cancer cancer survivors | #191 |
| twentyfive patients | #191 |
| manuscript | #192 |
| aspirin incidence | #192 |
| patients increases | #192 |
| chronic lymphedema | #192 |
| fortysix patients | #192 |
| aches | #192 |
| toxicity patients | #192 |
| treatment cancer patients | #192 |
| humans isoflavones | #193 |
| assigned receive | #193 |
| cimicifuga racemosa | #193 |
| effective agents | #194 |
| 25 women | #194 |
| weekly trastuzumab | #194 |
| ornithine decarboxylase activity | #195 |
| pain breast | #195 |
| 3 fatty | #195 |
| weight loss patients | #195 |
| resultsdata | #196 |
| acids double | #196 |
| pituitaryadrenal axis | #197 |
| trial designs | #197 |
| palonosetron dexamethasone | #197 |
| surveillance strategy | #198 |
| postmenopausal patients | #198 |
| resultstwo | #198 |
| toxicity profiles | #198 |
| women menopause | #199 |
| organization treatment | #199 |
| culminates | #199 |
| patients letrozole | #199 |
| delayed emesis | #199 |
| nicotine patch | #199 |
| accent | #199 |
| percent reduction | #200 |
| adjuvant interferon | #200 |
| oral glutamine | #201 |
| menopause premature | #201 |
| greater 5 | #202 |
| imiquimod | #202 |
| treatment bmd | #202 |
| item responses | #202 |
| primary goal | #202 |
| treatment week | #202 |
| hormonal treatments | #203 |
| bmd postmenopausal | #203 |
| cancer anemia | #203 |
| composition cachexia | #204 |
| plo | #204 |
| treated placebo | #204 |
| pelvic radiation therapy | #204 |
| induced oral | #205 |
| chemotherapy drugs | #206 |
| dalteparin | #206 |
| unwilling | #206 |
| udi6 | #206 |
| leucovorin patients | #206 |
| placebo 8 | #206 |
| mice cisplatin | #207 |
| heat hyperalgesia | #207 |
| pharmacologic interventions | #207 |
| reduced food intake | #208 |
| humans leucovorin | #208 |
| incurable | #208 |
| 4 8 weeks | #208 |
| 5 daily | #209 |
| hands patients | #209 |
| chemotherapy | #209 |
| lamotrigine | #210 |
| controlled evaluation | #210 |
| estrogen receptor modulators | #210 |
| methotrexate 5 | #210 |
| gel application | #211 |
| diagnosis recurrence | #212 |
| initials | #212 |
| methodsthis | #212 |
| regionally advanced | #212 |
| vomiting patients | #212 |
| charcotmarietooth disease | #213 |
| trial vitamin | #213 |
| docetaxel cyclophosphamide | #213 |
| dexamethasone control | #214 |
| placebo 6 weeks | #214 |
| oncology practices | #214 |
| patient weight | #214 |
| 15 minutes | #215 |
| antiemetic therapy | #215 |
| olanzapine 5 | #215 |
| oxaliplatin | #215 |
| december patients | #215 |
| neoplasms cross | #216 |
| prostate cancer survivors | #216 |
| tamoxifen users | #217 |
| gabapentin humans | #217 |
| women breast cancer | #217 |
| patients duloxetine | #217 |
| women tamoxifen | #217 |
| nonmajor | #218 |
| —reply | #218 |
| placebo weeks | #218 |
| purposethe purpose | #218 |
| hot | #218 |
| 10 daily | #218 |
| aprepitant | #218 |
| current management | #218 |
| life humans | #219 |
| palliative oncology | #219 |
| nmscs | #219 |
| transdermal fentanyl | #219 |
| sublingual administration | #220 |
| sexual symptoms | #220 |
| nonabsorbable | #220 |
| moderate pain | #221 |
| painful peripheral | #221 |
| ornithine decarboxylase odc | #221 |
| society clinical oncology | #221 |
| pregabalin patients | #221 |
| prospective study women | #222 |
| treatment postmenopausal | #222 |
| lymphedema patients | #222 |
| neoplasms palliative | #222 |
| ginkgo biloba egb | #222 |
| methylphenidate modafinil | #222 |
| relieving | #222 |
| primary breast cancer | #222 |
| furoate | #223 |
| randomized doubleblind study | #223 |
| prevention patients | #224 |
| 99 months | #225 |
| quinquefolius | #225 |
| computerized physician | #225 |
| partial mastectomy | #226 |
| agent patients | #226 |
| vaginal estrogen | #226 |
| bupropion | #227 |
| pain presence | #227 |
| turmoil | #227 |
| trial | #228 |
| clinical situation | #228 |
| 200 iu | #229 |
| nondiploid | #229 |
| secondary endpoint | #229 |
| antidepressive | #230 |
| akt inhibitor | #230 |
| physicians quality | #230 |
| eating disorders humans | #230 |
| placebo 10 | #230 |
| editorials | #230 |
| hospice patients | #230 |
| anthracycline cardiotoxicity | #230 |
| cancer recommendations | #230 |
| based adjuvant | #231 |
| rashes | #231 |
| vitamin effects | #231 |
| time study | #232 |
| handfoot syndrome | #232 |
| lightheadedness | #232 |
| conclusionsthe | #232 |
| cachexia cytokines | #232 |
| fluoxetine paroxetine | #233 |
| nonpharmacologic | #233 |
| treatment vte | #234 |
| acute symptoms | #234 |
| 4 doses | #234 |
| thirty women | #234 |
| women hot | #234 |
| day response | #235 |
| relieve | #235 |
| arm 95 | #235 |
| 375 day | #235 |
| sucralfate | #235 |
| tamoxifen neoplasms chemotherapy | #235 |
| effective treatments | #236 |
| placebo gel | #237 |
| premenopausal patients | #237 |
| flash | #238 |
| letrozole patients | #238 |
| postoperative monitoring | #238 |
| incidence grade | #238 |
| survivors treatment | #238 |
| antiemetics | #238 |
| improved bioavailability | #239 |
| overexpressing metastatic | #239 |
| methodswomen | #239 |
| nonpharmacologic interventions | #239 |
| chemotherapy placebo | #239 |
| adjuvant 5 | #239 |
| menopause middle | #239 |
| oncology clinic | #239 |
| oral complications | #240 |
| cachexia syndrome | #240 |
| treatment breast cancer | #240 |
| neoadjuvant therapy surgery | #240 |
| independent tests | #241 |
| stinging | #242 |
| participants randomized | #242 |
| aged paclitaxel | #243 |
| small doses | #243 |
| tetracycline | #244 |
| 3 arms | #245 |
| epoetin alfa | #245 |
| appetite stimulants | #246 |
| common practice | #246 |
| adjuvant oxaliplatin | #246 |
| efficacy placebo | #247 |
| mouthwashes | #248 |
| cachexia cancer | #248 |
| 800 iu | #249 |
| dysgeusia | #249 |
| item scores | #250 |
| randomized sham | #250 |
| survivors adult | #250 |
| loss bmd | #250 |
| major problems | #251 |
| patients physical | #251 |
| 689 | #251 |
| topic vitamin | #252 |
| menopause women | #252 |
| coasting | #252 |
| primary point | #253 |
| armodafinil | #253 |
| randomised studies | #253 |
| moderate degree | #254 |
| average intensity | #254 |
| nasal spray | #254 |
| chemotherapy breast | #255 |
| recurrence registries | #255 |
| longitudinal followup | #256 |
| prospective clinical | #256 |
| antidepressant | #257 |
| neoplasms randomized | #257 |
| therapy women | #257 |
| cancer treatment | #257 |
| new therapeutic approaches | #258 |
| dyspareunia | #258 |
| pretreatment levels | #258 |
| women treated | #258 |
| rigors | #259 |
| hydrochloride | #259 |
| opioid doseresponse relationship | #260 |
| tube cancer | #260 |
| inhibitors treatment | #260 |
| repeated measures | #261 |
| 1 baseline | #261 |
| common problem | #261 |
| patients cancer | #261 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| chronic post | #262 |
| decision framework | #263 |
| months treatment | #263 |
| dosage levels | #263 |
| management options | #263 |
| duloxetine placebo | #264 |
| treatment oxaliplatin | #264 |
| hematinics | #264 |
| phytogenic | #264 |
| outcome administration | #265 |
| recommendations quality | #265 |
| preoperative mri | #266 |
| treatmentrelated deaths | #266 |
| placebo 8 weeks | #267 |
| individual items | #267 |
| substantiation | #267 |
| surgery adjuvant | #267 |
| paresthesia | #267 |
| treatment cancer | #267 |
| adult cancer survivors | #268 |
| impact quality | #268 |
| 208 patients | #269 |
| ginkgo biloba | #270 |
| signaled | #270 |
| patients rash | #270 |
| nausea | #270 |
| estrogen antagonists | #271 |
| 80 90 | #271 |
| patients octreotide | #271 |
| moderate correlations | #271 |
| weekly | #272 |
| treatment 95 | #272 |
| control trials | #272 |
| bridged ring | #272 |
| dna test | #272 |
| performance status patients | #272 |
| distressing | #272 |
| score baseline | #272 |
| placebo‐controlled trial | #273 |
| abstinence rates | #273 |
| sham treatment | #274 |
| oncology clinical trials | #274 |
| dryness | #274 |
| gross disease | #275 |
| valeriana | #275 |
| induced cisplatin | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| treatment breast | #278 |
| perspiration | #278 |
| biomarkers disease humans | #279 |
| therapeutic options | #279 |
| patients symptoms | #279 |
| prominent | #279 |
| cimicifuga | #279 |
| patients hospice | #279 |
| individual patient | #280 |
| breast cancer outcomes | #280 |
| cholinergic antagonists | #280 |
| patients frequency | #280 |
| cartilage patients | #280 |
| psychometric testing | #281 |
| zoledronic acid patients | #281 |
| doxorubicin cyclophosphamide | #281 |
| chamomile | #282 |
| antidepressive agents | #282 |
| stage colon | #282 |
| completed questionnaires | #284 |
| women effects | #284 |
| greater severity | #284 |
| gabapentin treatment | #285 |
| smoking abstinence | #285 |
| early discontinuation | #286 |
| fatigue crf | #286 |
| acid adult | #287 |
| function quality | #287 |
| weeks patients | #287 |
| female hormone | #287 |
| symptoms function | #287 |
| colorectal lung | #287 |
| paps | #287 |
| aromatase inhibitor therapy | #288 |
| hot flush | #288 |
| life survival | #290 |
| eligible patients | #291 |
| discouraged | #292 |
| common symptom | #292 |
| clinical trial participation | #292 |
| treatment target | #292 |
| qualitative approach | #292 |
| mucositis oral | #293 |
| pain symptoms | #294 |
| weight gain patients | #294 |
| 1636 | #294 |
| cbdca | #294 |
| citalopram | #295 |
| testosterone supplementation | #295 |
| monographs | #295 |
| bone loss patients | #295 |
| vinca alkaloids | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| questionnaires treatment | #298 |
| aspirin placebo | #298 |
| patients entered | #298 |
| neoplasms cyclophosphamide | #299 |
| peripheral nervous | #299 |
| feet | #299 |
| inhibitors ais | #300 |
| hypothetical scenarios | #300 |
| radiation dermatitis | #300 |
| treated combination | #301 |
| shooting | #301 |
| octreotide | #302 |
| nogalamycin | #302 |
| survival trials | #302 |
| stage grade | #303 |
| acute neurotoxicity | #303 |
| treatment serum | #303 |
| nausea vomiting | #304 |
| symptoms pain | #304 |
| subscale scores | #304 |
| prospective clinical trial | #305 |
| prime time | #305 |
| complementary therapies | #305 |
| placebo groups | #305 |
| schedule female | #305 |
| global quality life | #306 |
| factg | #306 |
| aromatase inhibitor | #307 |
| prochlorperazine | #307 |
| placebo treatment | #307 |
| shortread | #307 |
| inflammatory breast cancer | #307 |
| aged cancer | #308 |
| drug embryo | #308 |
| neoplasms chemotherapy | #308 |
| apixaban | #308 |
| darbepoetin alfa | #309 |
| zoledronic acid | #310 |
| studies double | #310 |
| riskstratification | #311 |
| lung docetaxel | #311 |
| advanced cancer | #311 |
| individual subject | #311 |
| cancer receiving | #311 |
| testosterone placebo | #312 |
| placebo‐controlled | #312 |
| epoetin | #312 |
| musculoskeletal symptoms | #313 |
| patients cycle | #313 |
| or10 | #314 |
| syndrome aps | #314 |
| cancer adjuvant | #314 |
| new primary | #315 |
| operative chemotherapy | #315 |
| article evidence | #316 |
| organoplatinum | #316 |
| ambulatory patients | #317 |
| blinded | #317 |
| bfi | #317 |
| sesame oil | #317 |
| double‐blind | #317 |
| symptoms breast | #317 |
| rivaroxaban patients | #318 |
| efficacy treatment | #319 |
| irox | #319 |
| informed decisions | #321 |
| dietary counseling | #322 |
| life differences | #322 |
| thromboembolism anticoagulants | #323 |
| glutamine humans | #324 |
| smokers nicotine | #324 |
| monthly intervals | #324 |
| preventing | #325 |
| breast radiotherapy | #326 |
| nsclc chemotherapy | #326 |
| patients ductal carcinoma | #327 |
| compared baseline | #327 |
| titrate | #327 |
| continuation phase | #328 |
| lymphedema | #329 |
| treatment 1 year | #329 |
| antagonists female | #329 |
| vte cancer patients | #329 |
| patients resected | #329 |
| conducted evaluate | #329 |
| oral nutritional supplements | #329 |
| patients nasal | #330 |
| controlled clinical | #330 |
| arms | #330 |
| potential efficacy | #330 |
| future clinical trials | #330 |
| polymerase inhibitor | #331 |
| cancer ontario | #332 |
| lozenge | #332 |
| diagnosed primary | #332 |
| placebo patients | #334 |
| patients daily | #334 |
| 80 anemia | #334 |
| time disease | #335 |
| pain scale | #336 |
| 128 patients | #336 |
| ongoing clinical | #336 |
| paclitaxel therapy | #336 |
| relative benefits | #336 |
| sublingual | #337 |
| 5 fluorouracil | #337 |
| adjuvant letrozole | #337 |
| surveillance guidelines | #338 |
| survival 5 years | #338 |
| discernible | #339 |
| flutamide | #340 |
| order entry | #340 |
| mastectomy radiotherapy | #341 |
| treatment proportion | #341 |
| patients 4 weeks | #341 |
| eligible participants | #341 |
| cancer cachexia | #342 |
| fallopian tube cancer | #342 |
| osteopenia osteoporosis | #342 |
| tooth disease | #343 |
| society clinical | #343 |
| diseases quality | #343 |
| pilot randomized | #344 |
| epha5 | #345 |
| skeletal neoplasms | #345 |
| clinicians patients | #345 |
| accruing | #346 |
| mk2206 | #346 |
| clinical problems | #346 |
| adverse events groups | #347 |
| coumarin | #347 |
| therapy pain | #347 |
| mucositis patients | #348 |
| sham acupuncture | #349 |
| antineoplastic therapy | #349 |
| baseline quality | #350 |
| induced acute | #350 |
| vast majority | #350 |
| adjuvant folfox | #350 |
| treatment citalopram | #351 |
| dose schedule | #351 |
| dehydroepiandrosterone dhea | #351 |
| study therapy | #352 |
| paclitaxel | #353 |
| endodermal sinus | #353 |
| response letter | #353 |
| patientreported outcomes | #353 |
| letrozole | #355 |
| risedronate | #355 |
| cancer life | #355 |
| pain baseline | #356 |
| skin toxicities | #359 |
| vomiting | #359 |
| adjuvant colonic | #359 |
| potential benefit | #360 |
| cryotherapy | #360 |
| wellknown | #360 |
| ductal situ carcinoma | #360 |
| clin oncol | #360 |
| began | #361 |
| diaries | #361 |
| direct oral | #362 |
| pelvic radiation | #362 |
| nonpharmacological | #363 |
| ovarian suppression | #363 |
| calculators | #363 |
| cancer surveillance | #363 |
| pain measures | #363 |
| flaxseed | #363 |
| docetaxel paclitaxel | #365 |
| ovarian fallopian | #365 |
| cddp | #365 |
| completing | #365 |
| local prognosis receptor | #365 |
| pain cancer | #366 |
| optimal frequency | #366 |
| bioavailable testosterone | #366 |
| patients delayed | #366 |
| management cancer | #366 |
| scalp | #367 |
| weeks study | #368 |
| 5‐year | #368 |
| scale 0 | #368 |
| aged neoplasms | #369 |
| scheduled | #369 |
| hrt risk | #370 |
| skeletalrelated events | #371 |
| cancer received | #371 |
| orally daily | #372 |
| gamma aminobutyric acid | #372 |
| symptoms patients | #373 |
| skin toxicity | #373 |
| 5fluorouracil 5fu | #373 |
| irreversible damage | #374 |
| resected stage | #374 |
| ovarian failure | #374 |
| ecogps | #374 |
| paclitaxel dose | #374 |
| clinical oncology | #374 |
| −005 | #375 |
| therapy based | #376 |
| women breast | #376 |
| decreasing | #376 |
| medroxyprogesterone acetate | #377 |
| blood test | #377 |
| humans specificity | #378 |
| drowsiness | #378 |
| polyneuropathy | #378 |
| week patients | #378 |
| assessable patients | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| fura | #381 |
| loss skeletal | #381 |
| telerehabilitation | #381 |
| 4 treatment | #382 |
| leucovorin | #383 |
| unacceptable toxicity | #383 |
| organoplatinum compounds | #383 |
| 402 | #384 |
| function pain | #384 |
| patients capecitabine | #384 |
| trials involving | #384 |
| adverse event | #384 |
| disputes | #384 |
| target dose | #384 |
| 5fluorouracil leucovorin | #385 |
| leptin patients | #385 |
| conservation agents | #385 |
| fourths | #386 |
| density conservation | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| treatment women | #390 |
| glutathione gsh | #390 |
| advanced adenomas | #391 |
| aromatase inhibitors ais | #392 |
| sexual desire | #392 |
| 4 weeks | #394 |
| dying patients | #394 |
| adjuvant trials | #394 |
| early palliative | #395 |
| discontinuation rates | #396 |
| life breast | #396 |
| olanzapine | #397 |
| ring compounds | #397 |
| cytotoxics | #397 |
| performance score | #397 |
| humans mastectomy | #397 |
| paired tests | #398 |
| 1280 | #398 |
| patients randomly | #398 |
| life data | #399 |
| chemotherapy colorectal | #400 |
| intramuscular | #400 |
| questionnaires treatment outcome | #400 |
| withdrew | #400 |
| fatty acid supplementation | #400 |
| peripheral neurotoxicity | #400 |
| estrogen receptors biomarkers | #401 |
| assigned | #401 |
| 8090 | #401 |
| 3 cohorts | #401 |
| entered | #402 |
| loe | #402 |
| evidencebased | #402 |
| sadenosyllmethionine | #403 |
| acid female | #403 |
| female humans life | #403 |
| 5 weeks | #405 |
| baseline demographics | #406 |
| female fluorouracil | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| patients 5fu | #411 |
| life aged | #411 |
| topic neoplasms | #412 |
| female hemorrhage humans | #412 |
| regimens patients | #414 |
| ornithine decarboxylase | #414 |
| based chemotherapy | #415 |
| placebo 2 | #415 |
| oxaliplatin based | #415 |
| pain qol | #415 |
| acetate | #415 |
| oncology neoplasms | #416 |
| carboplatin patients | #416 |
| patient factors | #416 |
| platinum agents | #417 |
| gabapentinoids | #417 |
| delayed | #417 |
| prospective pilot | #417 |
| receiving | #418 |
| metastatic breast cancer | #419 |
| nighttime sleep | #419 |
| 0 4 | #419 |
| adjuvant hormonal therapy | #419 |
| case series patients | #419 |
| antiemetic prophylaxis | #420 |
| tcl1a | #421 |
| tamoxifen women | #421 |
| controlled pilot | #421 |
| cancer purpose | #421 |
| study entry | #421 |
| selfreported symptoms | #422 |
| directed therapy | #422 |
| severities | #422 |
| fourth week | #422 |
| 5 trials | #423 |
| arm 2 | #423 |
| pyridones | #423 |
| adequately | #423 |
| neurophysiologic | #424 |
| tamoxifen | #425 |
| androgen ablation | #425 |
| anastrozole | #425 |
| complementary alternative | #426 |
| ongoing clinical trials | #426 |
| prevention vte | #427 |
| baseline 6 weeks | #427 |
| gain adult | #428 |
| treating patients | #428 |
| primary peritoneal | #428 |
| greater percentage | #429 |
| creatine | #429 |
| desipramine | #430 |
| adjectives | #430 |
| fatigue humans | #431 |
| contraindicated | #431 |
| detection colorectal | #431 |
| laser therapy | #431 |
| hgb | #431 |
| methodsa | #431 |
| glycitein | #431 |
| symptom management | #432 |
| diploid tumors | #432 |
| antiseizure | #433 |
| joint symptoms | #433 |
| sunscreen | #433 |
| cancer tamoxifen | #434 |
| purpose objectives | #434 |
| resultsone | #434 |
| 115 patients | #434 |
| oral calcium | #435 |
| pains | #436 |
| olanzapine treatment | #436 |
| nutrition cancer | #436 |
| topic treatment | #436 |
| 1157 | #436 |
| absolute terms | #438 |
| clinical cancer | #438 |
| anthracyclinebased chemotherapy | #438 |
| nodenegative breast cancer | #439 |
| postoperative follow | #440 |
| administration cutaneous | #440 |
| neoplasms cancer | #441 |
| diminish | #441 |
| expected survival | #441 |
| vasomotor | #442 |
| yoga | #442 |
| baseline 1 month | #444 |
| hgpin | #444 |
| life efficacy | #445 |
| screening colorectal | #445 |
| doxorubicin drug administration | #445 |
| loss aged | #445 |
| preoperative breast | #445 |
| receive | #445 |
| marie | #446 |
| agents antineoplastic | #446 |
| day dexamethasone | #447 |
| acid aged | #447 |
| treatment regimen | #447 |
| 2 months | #448 |
| patients weight | #448 |
| european organization | #448 |
| patients qol | #448 |
| estrogen therapy | #449 |
| climacteric | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| cancer symptoms | #452 |
| baseline 4 weeks | #452 |
| study feasibility | #453 |
| outline | #453 |
| nodepositive breast cancer | #454 |
| arms arm | #454 |
| dhea | #455 |
| postmenopause | #455 |
| geranium | #456 |
| 5fu patients | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| questionnaires terminology | #461 |
| patients venous thromboembolism | #461 |
| enforced | #461 |
| cytokines patients | #462 |
| helpful | #462 |
| 6 weeks | #462 |
| patients baseline | #462 |
| increased weight | #463 |
| potential interventions | #463 |
| therapy stage | #464 |
| asco | #468 |
| clin | #468 |
| cancer institute | #468 |
| radiation enteritis | #469 |
| lung humans | #469 |
| referral centers | #469 |
| sexual distress | #470 |
| consensus guideline | #470 |
| purposethis | #471 |
| treatment options patients | #471 |
| esophagitis patients | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| pilocarpine | #474 |
| 432 | #474 |
| subscale | #474 |
| hormonal replacement therapy | #475 |
| groups 6 months | #475 |
| symptoms menopause | #475 |
| uncertain | #476 |
| preliminary studies | #477 |
| appears | #477 |
| single item | #477 |
| clinical decision making | #478 |
| placebo 24 weeks | #478 |
| variables age | #479 |
| doubleblind study | #479 |
| 95 placebo | #479 |
| onco | #479 |
| iii colon | #479 |
| enrollment patients | #480 |
| alopecia | #480 |
| vitamin placebo | #480 |
| osteoporosis osteopenia | #481 |
| crc 95 | #482 |
| moderatetosevere | #482 |
| higher dose | #483 |
| reluctance | #484 |
| adjuvant therapy | #484 |
| neurotoxicity patients | #485 |
| endpoints included | #485 |
| tpn | #485 |
| locoregional disease | #485 |
| 655 | #486 |
| cure | #486 |
| blind | #488 |
| taqman pcr | #488 |
| induced neuropathic | #489 |
| pain scores | #491 |
| doselimiting toxicity | #491 |
| estrogen deprivation | #491 |
| cancer cardiovascular disease | #492 |
| plant preparations | #493 |
| primary breast | #493 |
| combined modality treatment | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| fentanyl humans | #500 |
| patients breast cancer | #500 |
| received placebo | #501 |
| “ ” | #501 |
| placebo‐controlled study | #502 |
| pilot studies | #502 |
| life questionnaires survivors | #502 |
| kps | #502 |
| metastatic cancer | #503 |
| mesonephroma | #504 |
| loss patients | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| smoking nicotine | #511 |
| placebo trial | #511 |
| preventative | #512 |
| breast diseases | #513 |
| trials data | #513 |
| therapy aged | #513 |
| advance planning acp | #514 |
| flic | #514 |
| nonmetastatic breast cancer | #514 |
| evidencebased interventions | #515 |
| women receiving | #516 |
| letrozole treatment | #516 |
| premature menopause | #516 |
| outcome antineoplastic | #517 |
| serum albumin levels | #517 |
| acute diarrhea | #519 |
| achievements | #520 |
| pain medications | #520 |
| eflornithine | #521 |
| cbcs | #521 |
| pharmaceutic | #522 |
| gamma aminobutyric | #522 |
| poorer quality life | #523 |
| chills | #525 |
| symptoms fatigue | #525 |
| mastectomy middle | #525 |
| resultsto | #527 |
| prophylactic therapy | #528 |
| adverse events placebo | #528 |
| controlled crossover | #528 |
| phytogenic area | #529 |
| cmf | #529 |
| patients clinical trial | #529 |
| abt888 | #529 |
| therapy prostate | #530 |
| pregabalin | #531 |
| radiodermatitis | #531 |
| oncologists | #531 |
| centrally | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| patients evaluated | #536 |
| medications treatment | #536 |
| antineoplastic agents | #537 |
| study week | #538 |
| superficial bladder | #538 |
| weeks therapy | #538 |
| agents chemotherapy | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| pain patients | #543 |
| dehydroepiandrosterone | #543 |
| topic severity | #543 |
| pain score | #544 |
| risedronic | #544 |
| week 6 | #544 |
| 329 | #545 |
| 592 | #546 |
| peripheral | #548 |
| patients scheduled | #548 |
| unable | #549 |
| bmd baseline | #550 |
| receiving adjuvant | #550 |
| differences study | #551 |
| 3 95 | #552 |
| dabrafenib trametinib | #552 |
| hypesthesia | #553 |
| axonal transport | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| co2 laser | #556 |
| dysplastic lesions | #556 |
| neoplasms drug | #556 |
| evaluable | #556 |
| regular aspirin | #556 |
| abh | #557 |
| 300 day | #557 |
| vasomotor symptoms | #559 |
| rbc transfusions | #560 |
| emesis | #560 |
| 80000 | #560 |
| reported outcomes | #560 |
| moisturizer | #561 |
| day treatment | #561 |
| methylphenidate | #561 |
| mesna | #562 |
| hands | #564 |
| lmwh patients | #564 |
| time detection | #565 |
| method drug | #565 |
| induced cold | #565 |
| trial data | #566 |
| treatment periods | #566 |
| 4 8 | #567 |
| survival stage | #567 |
| supportive cancer | #567 |
| 11 months | #568 |
| therapy primary | #569 |
| calgb | #569 |
| scientifically | #569 |
| adjuvant clinical trials | #569 |
| lower dose | #571 |
| decarboxylase odc | #571 |
| topic treatment outcome | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| fluorouracil oxaliplatin | #578 |
| topical capsaicin | #578 |
| refute | #580 |
| patients candidates | #580 |
| methods systematic review | #580 |
| hwe | #581 |
| treatment phase | #581 |
| paced | #583 |
| breakthrough pain | #583 |
| paracentesis | #584 |
| life questionnaire | #584 |
| desvenlafaxine | #585 |
| moderate correlation | #585 |
| drug toxicity | #587 |
| neoplasms nutritional | #587 |
| paclitaxel carboplatin | #588 |
| emotional functioning | #589 |
| muscle cramps | #589 |
| oxaliplatin patients | #589 |
| aged occult | #589 |
| multiple cancers | #589 |
| limited efficacy | #589 |
| taxane chemotherapy | #590 |
| osteopenia | #590 |
| aminobutyric | #590 |
| acrin | #591 |
| median time progression | #592 |
| ablation therapy | #592 |
| crossover trial | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| pentoxifylline | #596 |
| compounded | #596 |
| fatigue female | #597 |
| exanthema | #597 |
| radiotherapy breast | #597 |
| sst2 | #597 |
| multisite | #598 |
| topic depressive disorder | #598 |
| patients mastectomy | #599 |
| initial surgery | #599 |
| publication administration | #599 |
| effects breast | #600 |
| thromboembolism vte | #600 |
| patients etanercept | #600 |
| statistically differences | #601 |
| health providers | #601 |
| discretion | #601 |
| 1093 | #601 |
| oral solution | #601 |
| patient decision | #601 |
| prevention measures | #602 |
| vte cancer | #602 |
| cfibers | #603 |
| cancer survivors | #604 |
| anthracycline based | #604 |
| exposed patients | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| 16 women | #608 |
| chemotherapy administration | #608 |
| toes | #608 |
| iron supplementation | #609 |
| agents antidepressive | #609 |
| management symptoms | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| 2 95 | #613 |
| pilot | #613 |
| updated analysis | #614 |
| montanide | #615 |
| qol baseline | #616 |
| animal data | #616 |
| 118 patients | #617 |
| humans quality | #617 |
| commonly | #618 |
| appetite | #620 |
| antacid | #620 |
| aic | #621 |
| persistent symptoms | #621 |
| urinary frequency | #621 |
| follow median | #622 |
| itching | #625 |
| gangliosides humans | #626 |
| analyzable | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| biological targets | #634 |
| mistletoe | #634 |
| month patients | #637 |
| female sexual function | #638 |
| serum hepcidin | #640 |
| dose placebo | #640 |
| assessment cancer | #640 |
| eligible | #641 |
| poorer quality | #642 |
| hormonal aromatase | #643 |
| inhibitors breast | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| nasal symptoms | #647 |
| palliative quality | #647 |
| 300 patients | #648 |
| malignant melanomas | #648 |
| symptoms | #649 |
| syndrome acute | #649 |
| doses patients | #651 |
| sores | #651 |
| method humans | #651 |
| flushes | #651 |
| appeared | #652 |
| dose limiting | #653 |
| opioid analgesic | #653 |
| limiting toxicity | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| colorectal adenocarcinoma | #662 |
| patients chemotherapy | #662 |
| 62 months | #663 |
| 95 − | #665 |
| alternative treatments | #666 |
| neoplasms patient | #666 |
| active agent | #666 |
| cancer prospective | #666 |
| nonparametric surveys | #667 |
| life radiotherapy | #667 |
| cancer treatments | #668 |
| levetiracetam | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| marie tooth | #671 |
| paclitaxel docetaxel | #671 |
| p00004 | #674 |
| axonopathy | #674 |
| pain adult | #674 |
| 1822 | #674 |
| maintenance disorders | #675 |
| pharmacologic management | #675 |
| racially | #676 |
| induced cognitive | #676 |
| patients standard | #678 |
| 5 consecutive | #678 |
| controlled study | #679 |
| routine follow | #680 |
| reported outcome | #681 |
| diethylstilbestrol | #681 |
| purpose report | #682 |
| study samples | #684 |
| oncology practice | #685 |
| popularly | #685 |
| highdose melphalan | #685 |
| deprivation therapy | #686 |
| therapy cancer | #687 |
| fluorouracil leucovorin | #687 |
| neurologic injury | #688 |
| sulindac | #688 |
| charcot marie | #688 |
| practice settings | #688 |
| pharmacological targeting | #692 |
| life survivors | #692 |
| rescue medication | #693 |
| guideline update | #693 |
| phlebitis | #694 |
| administration schedule | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| potential benefits | #699 |
| desmethyl | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| postmenopausal | #704 |
| chemopreventive agent | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| erythropoiesis stimulating | #712 |
| randomized studies | #712 |
| 160 | #712 |
| tube neoplasms | #714 |
| newer agents | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| inflammatory breast | #717 |
| lowmolecularweight heparin | #717 |
| convened | #719 |
| endorsement | #719 |
| ameliorate | #720 |
| erythropoietin female | #722 |
| data baseline | #722 |
| 6 months 95 | #725 |
| cyclophosphamide methotrexate | #725 |
| humans neoplasms | #725 |
| palliative medicine | #725 |
| therapeutic equivalency | #727 |
| physicians predictive | #728 |
| 4 hours | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| induced human | #731 |
| odc activity | #731 |
| study treatment | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| vinca | #735 |
| medroxyprogesterone | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| chemotherapy women | #738 |
| induced neurotoxicity | #738 |
| opd | #739 |
| mirtazapine | #741 |
| prescribing practices | #742 |
| locoregional therapy | #742 |
| 4 weeks patients | #742 |
| fist | #744 |
| women placebo | #745 |
| armamentarium | #745 |
| baseline 1 year | #745 |
| patients breast | #747 |
| bone loss | #748 |
| ecog | #748 |
| trials patients | #749 |
| chemotherapy initiation | #749 |
| psychostimulant | #750 |
| alfa | #750 |
| superficial bladder cancer | #750 |
| 271 | #750 |
| cervical dysplasia | #752 |
| rand | #752 |
| compared placebo | #753 |
| complementary medicine | #753 |
| radiation skin | #754 |
| 4·2 | #754 |
| oct2 | #754 |
| antigen levels | #754 |
| 46 | #755 |
| paclitaxel chemotherapy | #755 |
| trouble | #755 |
| secondary points | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| local anesthetics | #759 |
| rifngamma | #759 |
| reduction pain | #759 |
| sulfasalazine | #760 |
| prostate adenocarcinoma | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| occult blood | #766 |
| 81 patients | #766 |
| seventy patients | #766 |
| acid 4 | #768 |
| medroxyprogesterone acetate mpa | #768 |
| neoplasms prospective | #768 |
| baseline pain | #769 |
| humans imidazoles | #769 |
| activity breast | #770 |
| actual | #770 |
| sensory neuropathy | #771 |
| breast carcinoma ductal | #772 |
| modified radical mastectomy | #772 |
| relatedness | #772 |
| sweating | #772 |
| primary endpoint | #773 |
| women enrolled | #773 |
| keratinocyte growth factor | #773 |
| premenopausal women | #773 |
| emla | #774 |
| neoplasms breast | #774 |
| patients colon | #774 |
| fifty patients | #774 |
| 10 day | #774 |
| aged peripheral | #775 |
| octreotide treatment | #776 |
| acupuncture therapy | #776 |
| oral administration | #777 |
| 257 | #777 |
| p00002 | #778 |
| charcot | #778 |
| gsm | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| benefits patients | #785 |
| skin conductance | #785 |
| cutaneous administration | #785 |
| prognostic survival | #787 |
| enoxaparin | #788 |
| management | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| subsequent cycles | #793 |
| women reported | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| estrogen levels | #798 |
| potential treatments | #798 |
| clinical questions | #801 |
| neuralgia pain | #801 |
| life outcomes | #801 |
| osteoporosis women | #802 |
| erythropoiesisstimulating agents | #802 |
| lack efficacy | #804 |
| day 3 | #804 |
| randomized phase trial | #804 |
| primary points | #805 |
| glutathione | #805 |
| effects patients | #806 |
| double | #806 |
| 894 | #807 |
| opioid analgesia | #807 |
| etoposide cisplatin | #808 |
| continue | #808 |
| 3 day | #808 |
| 80 antineoplastic | #808 |
| placebotreated patients | #808 |
| 0025 | #809 |
| complete response | #811 |
| odc | #812 |
| abrogate | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| eastern cooperative | #820 |
| agents clinical | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| statisticians | #826 |
| tolerated | #826 |
| 148 patients | #827 |
| cancer control | #828 |
| rasch model | #828 |
| placebo 6 months | #830 |
| cancer phase | #830 |
| suggestive | #830 |
| administration oral | #830 |
| neoplasms bone | #832 |
| dabrafenib | #832 |
| humans medical | #833 |
| subset analysis | #833 |
| similarities differences | #835 |
| advanced malignancies | #836 |
| 366 | #836 |
| prognosis quality | #837 |
| mandelic | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| herbal products | #846 |
| adverse events aes | #846 |
| p006 | #847 |
| 142 patients | #848 |
| global qol | #848 |
| detection rates | #849 |
| toxicities | #850 |
| eortc | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| oncotype | #853 |
| n55 | #853 |
| stage ovarian | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| assessment management | #859 |
| taxoids | #859 |
| vaginal bleeding | #859 |
| stratification patients | #860 |
| published data | #860 |
| strongest | #864 |
| etidronic | #866 |
| placebo baseline | #868 |
| unacceptable | #868 |
| patients trial | #868 |
| efficacious | #873 |
| jellies | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| symptomatic women | #880 |
| nonpharmacological interventions | #880 |
| phytogenic carcinoma | #880 |
| midlife women | #881 |
| antineoplastic | #883 |
| 450 | #883 |
| study placebo | #883 |
| monoclonal antineoplastic agents | #885 |
| mitigates | #889 |
| neurotoxic | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| cancer guidelines | #894 |
| caa | #894 |
| control arm | #896 |
| completed | #900 |
| neoplasms hormone | #901 |
| oxy | #901 |
| women hormone | #902 |
| inconvenience | #903 |
| percent | #903 |
| nodal status | #903 |
| nmsc | #904 |
| 00006 | #905 |
| provided | #905 |
| chemotherapy response | #905 |
| survival surgery | #905 |
| hospices | #909 |
| chemotherapeutic | #910 |
| increased risk death | #910 |
| cancer studies | #913 |
| national cancer | #914 |
| weight maintenance | #914 |
| norepinephrine reuptake | #915 |
| life cancer patients | #916 |
| paroxetine | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| advanced cancer patients | #921 |
| mouth mucosa | #921 |
| evidence practice | #923 |
| population cohort | #924 |
| manuscripts | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| oral dosing | #929 |
| upper extremities | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| serotonin uptake | #939 |
| electronic health record | #939 |
| treatment symptoms | #940 |
| visual analogue | #940 |
| 138 patients | #942 |
| advanced adenoma | #943 |
| high‐risk | #943 |
| uptake inhibitors | #943 |
| colorectal adenomas | #944 |
| letter editor | #944 |
| patient population | #944 |
| gp100 | #945 |
| iii topic | #945 |
| beckman | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| orally | #954 |
| jci | #954 |
| evaluating | #955 |
| participating centers | #955 |
| cooperative oncology | #957 |
| hfs | #958 |
| aloe vera | #958 |
| adjuvant therapies | #958 |
| rheumatologic | #958 |
| erythropoietic | #959 |
| leukopenia | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| trpm8 | #963 |
| pjnk | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| table | #972 |
| earlystage disease | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| olmsted county | #977 |
| restarted | #977 |
| hypercalcemia | #978 |
| 1 10 | #978 |
| 1month | #980 |
| mechanical allodynia | #980 |
| 2700 | #982 |
| 1 week | #984 |
| antidotes | #984 |
| 150 | #984 |
| patients venous | #989 |
| threequarters | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| bother | #1003 |
| mayo | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| fatigue patients | #1028 |
| enteritis | #1028 |
| urogenital | #1030 |
| alternative treatment | #1031 |
| delayed treatment | #1031 |
| pill | #1037 |
| evidence treatment | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| postural control | #1044 |
| prx | #1044 |
| randomized trial patients | #1046 |
| colorectal tumor | #1047 |
| patients safety | #1047 |
| prevention intervention | #1047 |
| substantial | #1050 |
| frey | #1051 |
| nutritional supplementation | #1051 |
| life | #1053 |
| 30 40 | #1053 |
| doxorubicin female humans | #1056 |
| postchemotherapy | #1056 |
| minority | #1057 |
| primary analysis | #1059 |
| feeding eating | #1059 |
| osteoporosis treatment | #1059 |
| 10 weeks | #1060 |
| tricyclic | #1061 |
| day study | #1061 |
| oncologist | #1063 |
| prospective validation | #1063 |
| fruitful | #1063 |
| endocrine resistance | #1064 |
| 347 | #1064 |
| ongoing studies | #1066 |
| loss weight | #1066 |
| therapy | #1069 |
| disappointing | #1069 |
| suggested | #1069 |
| practical guidance | #1070 |
| metastatic lung | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| concurrent chemotherapy | #1078 |
| nccn | #1078 |
| monoclonal humans | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| breast cancer recurrence | #1089 |
| prompted | #1089 |
| duloxetine | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| postoperative surveillance | #1095 |
| palonosetron | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| favor | #1099 |
| intravenous iron | #1099 |
| agents treatment | #1100 |
| functional ability | #1100 |
| previous chemotherapy | #1100 |
| 54 | #1103 |
| phytoestrogens | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| cancer trials | #1126 |
| interprofessional relations | #1126 |
| prilocaine | #1127 |
| dmc | #1127 |
| unpleasant | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| clinician | #1133 |
| patients versus | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| opioid therapy | #1139 |
| 25 micrograms | #1139 |
| practice guideline | #1140 |
| hormonal therapy | #1140 |
| cancer | #1141 |
| inhibit | #1144 |
| purposeto | #1144 |
| egb | #1146 |
| cancer pain | #1146 |
| randomized crossover | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| purpose determine | #1150 |
| premature ovarian failure | #1150 |
| shark | #1150 |
| nervousness | #1153 |
| 730 | #1153 |
| smoking prevention | #1154 |
| detrimental | #1154 |
| hormonal | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| rinse | #1162 |
| 22 | #1162 |
| doac | #1163 |
| educate | #1164 |
| toxicity assessment | #1167 |
| purposethis study | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| painful | #1174 |
| therapy estrogens | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| prior treatment | #1189 |
| international consensus | #1189 |
| acetate treatment | #1190 |
| mastectomy breast | #1190 |
| usage | #1193 |
| gained | #1196 |
| estrogen replacement therapy | #1197 |
| olmsted | #1197 |
| diary | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| male smokers | #1204 |
| partial responses | #1204 |
| 552 | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| breast cancer | #1212 |
| satisfied | #1212 |
| induced skin | #1213 |
| 611 | #1215 |
| patients pts | #1215 |
| communication skills | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| secondary endpoints | #1219 |
| sexuality | #1219 |
| precludes | #1219 |
| 8 week | #1221 |
| phase clinical trial | #1223 |
| higher numbers | #1223 |
| limiting | #1224 |
| thighs | #1227 |
| editor | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| primary melanomas | #1232 |
| 8 weeks | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| discontinue | #1235 |
| randomized phase | #1235 |
| clinical syndrome | #1241 |
| tricyclic antidepressants | #1241 |
| baseline values | #1245 |
| symptoms diagnosis | #1248 |
| review data | #1248 |
| day 2 | #1248 |
| decided | #1249 |
| etiologies | #1250 |
| female sexual | #1250 |
| postmenopausal women | #1252 |
| bedtime | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| thromboembolism patients | #1258 |
| diphosphonates | #1258 |
| combination docetaxel | #1258 |
| trametinib | #1259 |
| hypochromic | #1259 |
| patients 4 | #1259 |
| rasch | #1260 |
| kidney dysfunction | #1260 |
| pain medication | #1261 |
| neurologic humans | #1263 |
| doubts | #1263 |
| dna ploidy | #1265 |
| tumor promotion | #1265 |
| sae | #1266 |
| esophagitis | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| qol scores | #1272 |
| drug double | #1272 |
| short form36 | #1273 |
| situ carcinoma ductal | #1273 |
| patients families | #1274 |
| preoperative chemotherapy | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| taxanes | #1279 |
| tamoxifen patients | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| cyclophosphamide doxorubicin | #1289 |
| opposed | #1289 |
| adjuvant therapy patients | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| acupuncture treatment | #1294 |
| cochran | #1294 |
| data clinical | #1296 |
| prevalence severity | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| abstinent | #1307 |
| 8 cycles | #1307 |
| stimulating agents | #1309 |
| survival 5 | #1310 |
| motion rom | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| melanoma antigen | #1315 |
| biotech | #1315 |
| gsh | #1315 |
| breast biopsy | #1317 |
| contacted | #1318 |
| durations | #1318 |
| etanercept | #1320 |
| health‐related quality | #1320 |
| chemotherapeutic agents | #1321 |
| investigative | #1321 |
| oncology patients | #1321 |
| controlled | #1321 |
| primary outcome measure | #1322 |
| pain interference | #1322 |
| patients quality | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| patient physician | #1328 |
| life scores | #1328 |
| agents colorectal | #1329 |
| cardiac toxicity | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| breast cancer women | #1347 |
| platinum compounds | #1347 |
| colonoscopic | #1350 |
| experienced | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| cancer experience | #1353 |
| benefit patients | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| patients colon cancer | #1382 |
| n32 | #1382 |
| n29 | #1382 |
| duplicates | #1386 |
| mastectomy | #1387 |
| hydrazines | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| polyneuropathies | #1407 |
| rifn | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| viscum | #1416 |
| wilcoxon | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| sleep initiation | #1424 |
| noncompliance | #1424 |
| subjective symptoms | #1424 |
| biloba | #1425 |
| methodsdata | #1426 |
| therapy initiation | #1426 |
| prevent | #1427 |
| cancer quality life | #1427 |
| cytotoxic chemotherapy | #1428 |
| hormonal treatment | #1431 |
| aromatase | #1431 |
| and or | #1432 |
| weight heparin | #1433 |
| 5fu | #1433 |
| statistically difference | #1434 |
| radiation injuries | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| proctitis | #1445 |
| goserelin | #1445 |
| aminobutyric acid | #1446 |
| ehrs | #1447 |
| postacute | #1447 |
| cancer clinical trials | #1449 |
| incidences | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| treatment pain | #1454 |
| patients ovarian | #1454 |
| nccn guidelines | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| dna testing | #1461 |
| effective management | #1461 |
| individual patients | #1461 |
| adjuvant treatment | #1463 |
| aged quality | #1466 |
| life cancer | #1466 |
| discrepancies | #1467 |
| haloperidol humans | #1467 |
| network meta | #1467 |
| crossover | #1468 |
| locally advanced head | #1469 |
| nutritional support | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| life treatment | #1477 |
| hormone dependent | #1477 |
| substantial proportion | #1479 |
| resultsa | #1479 |
| lower extremities | #1483 |
| tumor promoter | #1484 |
| oral aged | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| resultsafter | #1501 |
| paclitaxel cisplatin | #1501 |
| mpa | #1509 |
| anti anxiety | #1510 |
| colon cancer patients | #1510 |
| gynecologic cancer | #1513 |
| perimenopause | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| biweekly | #1523 |
| efficacy | #1523 |
| hair loss | #1523 |
| p0024 | #1525 |
| diagnosed cancer | #1525 |
| oncology | #1526 |
| root ganglion | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cck8 | #1537 |
| cytotoxic agents | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| blind randomized | #1562 |
| male breast | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| iii disease | #1576 |
| pharmacologic treatment | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| crushed | #1583 |
| rivaroxaban | #1583 |
| patients small | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| image body | #1593 |
| dissent | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| trpa1 | #1600 |
| stratification | #1600 |
| therapy cyclophosphamide | #1602 |
| aged cross | #1603 |
| completion | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| oncology nursing | #1624 |
| 970 | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| 2003 | #1652 |
| controlled phase | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| populationbased cohort | #1667 |
| breast cancer patients | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| neoplasms practice | #1693 |
| anticancer therapy | #1693 |
| weight patients | #1694 |
| stopping | #1695 |
| percent patients | #1695 |
| ≤2 | #1696 |
| methyldopa | #1696 |
| nootropic | #1698 |
| randomization | #1698 |
| patients bone | #1698 |
| morpholines | #1700 |
| symptom distress | #1701 |
| patients control | #1701 |
| endpoint | #1703 |
| enrolled patients | #1705 |
| glutamine | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| chemotherapy patients | #1709 |
| 595 | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| effects cancer | #1726 |
| human epidermal | #1726 |
| selective estrogen | #1728 |
| referral consultation | #1728 |
| 652 | #1729 |
| testosterone treatment | #1729 |
| nineteen | #1730 |
| orchiectomy | #1731 |
| neuropathic pain | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| p450 cyp2d6 | #1746 |
| topical | #1746 |
| ≥10 | #1749 |
| oxcarbazepine | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| unique challenges | #1754 |
| neoplasms early | #1754 |
| insufficient evidence | #1762 |
| treatment data | #1762 |
| greater reduction | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| massage | #1766 |
| grade 2 | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| 95 0 | #1781 |
| clinical endpoints | #1781 |
| objective responses | #1784 |
| fingers | #1784 |
| lignans | #1785 |
| behavioral interventions | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| survival outcomes patients | #1791 |
| life assessment | #1791 |
| anorectic | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| primary therapy | #1796 |
| alternative medicine | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| acetylcarnitine | #1803 |
| treatment cycles | #1803 |
| severe toxicity | #1804 |
| median survival time | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| 16 patients | #1813 |
| agents female | #1813 |
| breast surgery | #1816 |
| evidencebased recommendations | #1818 |
| trpm | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| cancer women | #1823 |
| 327 | #1823 |
| evaluable patients | #1825 |
| effective therapy | #1825 |
| anxiety agents | #1827 |
| humans neoplasm | #1831 |
| ganglion neurons | #1831 |
| longterm survival patients | #1835 |
| neoplasms prognosis | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| comprehensive cancer | #1851 |
| months 12 | #1851 |
| dermatological | #1853 |
| neuropathic | #1853 |
| patients prognosis | #1853 |
| 23 months | #1853 |
| providers patients | #1857 |
| cancer types | #1858 |
| initial dose | #1858 |
| aged postmenopause | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| humans pain | #1873 |
| europe female humans | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| induced pain | #1879 |
| resultsa total | #1879 |
| musculoskeletal pain | #1881 |
| analysis adult | #1881 |
| antigen colorectal | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| schedules | #1891 |
| questionnaires time | #1891 |
| keratinocyte | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| stellate | #1899 |
| problematic | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| prematurely | #1946 |
| health personnel attitude | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| primary aim | #1971 |
| iii breast | #1971 |
| warrant | #1972 |
| articles | #1974 |
| surveillance colonoscopy | #1974 |
| initiating | #1975 |
| clinical patients | #1978 |
| estrogen replacement | #1978 |
| hand foot | #1979 |
| collaborative | #1982 |
| intravaginal | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| cancer patient | #1994 |
| androgen antagonists | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| phytotherapy plant | #2018 |
| form36 | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| critics | #2025 |
| perimenopausal | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| evidence base | #2056 |
| status patients | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| cancer population | #2069 |
| relaxation therapy | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| daily | #2075 |
| safety pharmacokinetics | #2075 |
| hb level | #2075 |
| vinblastine | #2076 |
| 50 reduction | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| younger women | #2087 |
| iii | #2087 |
| patients caregivers | #2088 |
| nursing practice | #2090 |
| advanced cancers | #2090 |
| antidote | #2090 |
| major bleeding | #2094 |
| cco | #2094 |
| weekly paclitaxel | #2097 |
| 66 years | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| orally administered | #2111 |
| tmt | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| ≥2 | #2121 |
| bmd lumbar spine | #2121 |
| 5fluorouracil | #2122 |
| 96 patients | #2124 |
| treatment study | #2124 |
| journals | #2125 |
| mildly | #2126 |
| hb levels | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| secondary objectives | #2136 |
| egfr inhibitors | #2136 |
| concerned | #2136 |
| 525 | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| evidence efficacy | #2166 |
| baseline | #2166 |
| treatment acute | #2169 |
| anemic | #2169 |
| aloe | #2175 |
| women | #2177 |
| worst | #2179 |
| pain syndromes | #2179 |
| album | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| dose intensity | #2208 |
| 455 | #2208 |
| prescription drugs | #2210 |
| female head | #2210 |
| age race | #2210 |
| 1 7 | #2212 |
| ensuing | #2213 |
| hypnosis | #2213 |
| weight loss | #2214 |
| recurrences | #2220 |
| 1–4 | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| osteonecrosis jaw | #2235 |
| 9 weeks | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| failed | #2247 |
| adrenal axis | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| 1 year patients | #2285 |
| oophorectomy | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| life illness | #2301 |
| therapy adt | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| polymerase inhibitors | #2310 |
| conclusionthe | #2310 |
| patch | #2311 |
| recommendation | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| 74 | #2327 |
| baclofen | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| mastectomy segmental | #2333 |
| burning | #2333 |
| 36 | #2333 |
| toxicity | #2334 |
| modest | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| society | #2347 |
| opioid analgesics | #2347 |
| androgen deprivation | #2349 |
| improve quality | #2349 |
| 46 patients | #2352 |
| curve analysis | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| density bmd | #2365 |
| cyp2d6 | #2365 |
| baseline treatment | #2367 |
| increased risks | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| counteract | #2405 |
| 266 | #2405 |
| titles | #2406 |
| treatment baseline | #2407 |
| inadequate | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| rectal cancer patients | #2419 |
| poor performance | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| 5 patients | #2425 |
| advanced prostate cancer | #2425 |
| symptom scores | #2426 |
| limited evidence | #2426 |
| debate | #2433 |
| 761 | #2436 |
| practiced | #2437 |
| 71 patients | #2437 |
| patients crc | #2439 |
| estrogen deficiency | #2439 |
| response evaluation | #2442 |
| acupuncture | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| factor inhibitors | #2469 |
| assessment scale | #2469 |
| fallopian | #2474 |
| 207 | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| ginkgo | #2510 |
| 61 | #2510 |
| locoregional | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| asked | #2542 |
| amitriptyline | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| 12 24 | #2556 |
| treatment methods | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| telopeptide | #2567 |
| randomised clinical trial | #2567 |
| nitriles | #2568 |
| reuptake | #2570 |
| treatment selection | #2570 |
| stage small | #2573 |
| earlystage breast cancer | #2573 |
| conjunctivitis | #2574 |
| trials | #2592 |
| secondary analyses | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| outcome united | #2624 |
| antineoplastic combined | #2624 |
| apr | #2626 |
| consented | #2626 |
| suspicious | #2627 |
| dorsal root | #2629 |
| symptoms quality | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| races | #2657 |
| thromboembolism | #2657 |
| 0001 patients | #2657 |
| attenuate | #2662 |
| total parenteral nutrition | #2663 |
| scores | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| chemotherapy protocols | #2745 |
| modestly | #2745 |
| thermal hyperalgesia | #2748 |
| multiple factors | #2749 |
| acp | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| 1 4 | #2775 |
| male neoplasms | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| pooled data | #2790 |
| paraneoplastic syndromes | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| isoflavones | #2794 |
| ascites | #2794 |
| agents | #2797 |
| complete data | #2799 |
| nv | #2801 |
| thrice | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| meeting | #2844 |
| opioids | #2844 |
| primary outcomes | #2845 |
| 38 | #2845 |
| cancer aged | #2854 |
| cohen | #2857 |
| n31 | #2857 |
| linseed | #2859 |
| breakthrough | #2859 |
| neoplasms | #2860 |
| pharmacogenomic | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| activity level | #2867 |
| breaths | #2867 |
| purposethe | #2869 |
| anticipate | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| 5 years patients | #2886 |
| task force | #2886 |
| ellipse | #2893 |
| survival dose | #2895 |
| p04 | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| prior | #2931 |
| condylomata | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| identifier | #2949 |
| review articles | #2949 |
| dosing regimens | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| calories | #2991 |
| started | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| objective response | #3012 |
| n5 | #3012 |
| topically | #3013 |
| discomfort | #3014 |
| time progression | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| reuptake inhibitors | #3041 |
| her2 status | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| relief | #3058 |
| risk colorectal | #3058 |
| dukes | #3058 |
| tumor activity | #3066 |
| curve auc | #3067 |
| outcome measure | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| vera | #3111 |
| bmd | #3111 |
| cancer female humans | #3111 |
| 66 | #3116 |
| neurokinin1 | #3121 |
| 26 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| supportive | #3185 |
| current approaches | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| joint committee | #3225 |
| intervention trial | #3225 |
| 39 | #3226 |
| nonsmallcell lung cancer | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| itch | #3260 |
| therapy combination | #3260 |
| intervention patients | #3263 |
| designed | #3264 |
| oral mucosa | #3264 |
| 236 | #3266 |
| prior studies | #3269 |
| disagree | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| root ganglia | #3287 |
| 2030 | #3287 |
| 80 antibodies | #3288 |
| 695 | #3290 |
| 885 | #3290 |
| lymphoma patients | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| impression | #3320 |
| treatment placebo | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| 171 | #3334 |
| acuminata | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| bone metastases | #3370 |
| doubt | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| screening methods | #3446 |
| 012 | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| 64 patients | #3463 |
| utilizing | #3463 |
| sprays | #3464 |
| survival benefits | #3468 |
| listed | #3468 |
| pts | #3468 |
| chemotherapy radiation | #3471 |
| anthracyclines | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| survival women | #3583 |
| phase topic | #3583 |
| correlational | #3583 |
| 135 | #3586 |
| carboplatin paclitaxel | #3586 |
| oestrogen | #3587 |
| patients experiences | #3588 |
| chemotherapy cycles | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| life qol | #3608 |
| objective measures | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| survival cancer | #3620 |
| benefits risks | #3620 |
| ≥30 | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| colon cancer | #3650 |
| ordinal | #3650 |
| patients adjuvant chemotherapy | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| 673 | #3682 |
| sigmoidoscopy | #3682 |
| preceded | #3685 |
| proportion | #3686 |
| 580 | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| foams | #3742 |
| randomized clinical trial | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| terminal | #3811 |
| hormone replacement | #3811 |
| anesthetics | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| intramuscularly | #3834 |
| patients experienced | #3834 |
| 136 | #3839 |
| 16 weeks | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| trpv | #3847 |
| contraindications | #3847 |
| blinding | #3854 |
| seventy | #3854 |
| patients grade | #3855 |
| sharks | #3855 |
| internally | #3858 |
| treatment metastatic | #3861 |
| 23 | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| publication clinical trials | #3940 |
| myoclonus | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| lasting | #4002 |
| weight | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| audio | #4034 |
| patients intervention | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| erythropoietin | #4062 |
| prostatic | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| cancer therapy | #4069 |
| conjunction | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| favoring | #4126 |
| noninfiltrating | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| definitions | #4138 |
| topic practice patterns | #4138 |
| tablets | #4138 |
| malignant melanoma | #4139 |
| femoral neck | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| cancer bone | #4210 |
| depressants | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| neoplasms colorectal | #4258 |
| contraindication | #4258 |
| serially | #4268 |
| treatment discontinuation | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| bone density | #4284 |
| survival quality | #4284 |
| day | #4285 |
| inconsistencies | #4289 |
| utilized | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| reductions | #4326 |
| prednisolone | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| primary endpoints | #4331 |
| healthy women | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| neoplasms combined | #4359 |
| institute | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| repeatedly | #4402 |
| drug combinations | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| 80 breast | #4431 |
| studies colorectal | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| improve patient | #4446 |
| day patients | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| 80 | #4465 |
| pain measurement | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| daily activities | #4523 |
| 5 | #4523 |
| sedation | #4529 |
| ganglion | #4530 |
| gynecologic | #4530 |
| ductal breast | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| stimulant | #4536 |
| disabling | #4536 |
| sphingolipids | #4537 |
| natural | #4537 |
| diarrhea | #4540 |
| drug effects | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| rescue therapy | #4564 |
| clinical | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| 4 | #4575 |
| reliability validity | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| hydroxytryptamine | #4591 |
| risk bleeding | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| neuropathies | #4647 |
| daily dose | #4647 |
| 6 12 | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| adpribose | #4665 |
| dose chemotherapy | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| ” | #4734 |
| mediastinum | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| 009 | #4806 |
| corticosteroid | #4806 |
| tears | #4810 |
| 538 | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| improved quality | #4818 |
| cancer compared | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| multicenter | #4836 |
| symptom burden | #4836 |
| carcinoma small | #4837 |
| bridged | #4837 |
| seer program | #4841 |
| tubulin | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| screening tool | #4956 |
| sensitization | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| genistein | #5084 |
| karnofsky performance | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| version | #5104 |
| pyrimidinones | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| physical therapy | #5131 |
| reducing | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| identical | #5243 |
| dying | #5243 |
| randomised controlled trial | #5244 |
| article | #5249 |
| humans lung | #5249 |
| insomnia | #5255 |
| patients time | #5257 |
| conventionally | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| low molecular | #5270 |
| caring | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| anticipated | #5335 |
| alkaloids | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| perceived | #5359 |
| sensation | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| stage iii | #5423 |
| officinalis | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| sensory | #5638 |
| treatment approaches | #5638 |
| new therapies | #5642 |
| lung carcinoma | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| renewed | #5694 |
| dexamethasone | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| complete | #5730 |
| specialist | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| interruption | #5762 |
| tumor breast | #5762 |
| tumor stage | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| carcinoma situ | #5783 |
| nicotine | #5783 |
| mucous | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| interfere | #5877 |
| 405 | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| 1977 | #6013 |
| insulinlike growth factor | #6013 |
| prognostic indicator | #6018 |
| descriptions | #6019 |
| minute | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| 0013 | #6041 |
| chemotherapy radiotherapy | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| psychotropic drugs | #6280 |
| disclosure | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| insignificant | #6302 |
| benzhydryl | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| fentanyl | #6372 |
| aged | #6372 |
| 2007 | #6385 |
| venous thromboembolism vte | #6385 |
| infusions | #6393 |
| epidermal growth | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| psychotropic | #6439 |
| pittsburgh | #6439 |
| multinational | #6440 |
| entire | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| intraluminal | #6471 |
| 75 | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| hemoglobins | #6612 |
| l3 | #6612 |
| decisions | #6614 |
| 287 | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| pellet | #6646 |
| guidelines | #6646 |
| crf | #6648 |
| patients health | #6651 |
| hormone receptor | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| erectile dysfunction | #6694 |
| caloric | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| hypothesized | #6702 |
| radiotherapy chemotherapy | #6702 |
| ketamine | #6710 |
| colorectal cancer patients | #6717 |
| consecutive | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| replacement therapy | #6751 |
| quit | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| search strategy | #6801 |
| frequently | #6801 |
| longest | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| controlled studies | #6810 |
| fulfilled | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| factors breast | #6942 |
| cbd | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| skin temperature | #6981 |
| regressions | #6981 |
| ais | #6986 |
| calorie | #6990 |
| quiet | #6990 |
| wearing | #6990 |
| 35 | #6994 |
| definition | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| patients 1 | #7067 |
| interested | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| prostate cancer | #7130 |
| neoplasms female | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| ameliorates | #7264 |
| questionnaire | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| outpatients | #7296 |
| neoplasms primary | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| superficial | #7353 |
| evaluates | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| curative | #7416 |
| rfs | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| receptor agonists | #7436 |
| emphasis | #7436 |
| confirmatory | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| wasting | #7488 |
| prognosis proportional | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| investigators | #7534 |
| infertility | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| ploidy | #7624 |
| interval | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| monitored | #7699 |
| 1 day | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| surveys | #7725 |
| 021 | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| washout | #7744 |
| administration | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| impacted | #7927 |
| ago | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| 5year survival | #7956 |
| comparing | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| intractable | #8063 |
| genders | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| regard | #8249 |
| patients adult | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| pharmacogenetics | #8372 |
| year follow | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| undergoing | #8422 |
| preparations | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 3 trial | #8482 |
| 37 | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| estrogen receptors | #8637 |
| morphine | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| single nucleotide polymorphisms | #8700 |
| notable | #8700 |
| molecular markers | #8705 |
| threatening | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| mouth | #8800 |
| real | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| favored | #9020 |
| longer | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| systematic literature | #9317 |
| 94 | #9317 |
| 15 | #9332 |
| possess | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| mechanisms action | #9383 |
| acceptable | #9383 |
| ambulatory | #9385 |
| drug female | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| partial response | #9454 |
| definitive | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| cancer crc | #9542 |
| 500 | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| monoclonal humanized | #9791 |
| priority | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| clinical outcomes patients | #9872 |
| avoid | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| prescribing | #10007 |
| reactions female | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| changed | #10400 |
| survival dfs | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| mineral density | #10522 |
| longitudinal studies | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| doxorubicin | #10617 |
| counselling | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| enter | #10757 |
| anticoagulants | #10757 |
| fat mass | #10763 |
| median duration | #10779 |
| iiia | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| clinic | #10803 |
| 182 | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| international society | #11105 |
| smoking | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| practice guidelines | #11135 |
| sick | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| clinical signs | #11439 |
| apparent | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| 235 | #11509 |
| caregivers | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| definite | #11855 |
| 024 | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| referral | #11997 |
| 1998 | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| sodium channel | #12270 |
| peri | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| fourteen | #12657 |
| rank test | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| future | #13082 |
| humans logistic | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| humans lymphatic | #13262 |
| epidemiologic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| agonists | #13630 |
| improves | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| marked | #13813 |
| 18 years | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| lung cancer | #14080 |
| substances | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| protective | #14195 |
| modality | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| states aged | #14282 |
| careful | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| analysis performed | #14341 |
| instance | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| 144 | #14420 |
| produces | #14420 |
| 4 patients | #14436 |
| nodal | #14440 |
| extremity | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| episodes | #14626 |
| 09 | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| adult | #14729 |
| 008 | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| 15 years | #14762 |
| neoplasm | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| colonoscopy | #15187 |
| assessments | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 197 | #15404 |
| 131 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| updated | #15749 |
| option | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| glandular | #15882 |
| local | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| phenomenon | #16013 |
| usa | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| analysis survival | #16209 |
| 161 | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| supported | #16222 |
| neoadjuvant | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| detection cancer | #16320 |
| neurotransmitter | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| improvements | #16418 |
| diagnostic imaging | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| understand | #16705 |
| male neoplasm | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| major | #16886 |
| rarely | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| diseasefree survival | #17162 |
| iron deficiency | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| mood | #19177 |
| inhibitor | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| 2005 | #22223 |
| authors | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| diverse | #23033 |
| imaging mri | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2011 | #23997 |
| 2017 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
Sacar un reporte | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| Conocido por Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| Conocido por Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| Conocido por Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| Conocido por Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| Conocido por Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| Conocido por Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| Conocido por Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| Conocido por Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| Conocido por Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| Conocido por Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| Conocido por Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| Conocido por Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| Conocido por Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
Gente clave para Hot Flashes
Los KOLs mas influyentes del mundo
Seleccione una frase de búsqueda hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:Impacto experto
Conceptos para los cualesCharles L Loprinzitiene influencia directa:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:Impacto de Kol
Conceptos relacionados con el trabajo de otros autores para los cualesfor which Charles L Loprinzi tiene influencia:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
¿Es este tu perfil? Reclama tu perfil Copiar URL Incrustar el enlace a su perfil |